

43/RSP24

44/RSP25

58/RSP35

REPLACED SHEETS . SG

☒ Description : paged ...1... to paged ...101...
☒ Claim(s) : paged ...102... to paged ...104...
☐ Drawing(s) : paged to paged
☒ Abstract : paged ...41... to paged
DATE OF RECEIPT

- 1 -

18197Y

10

TITLE OF THE INVENTION

NOVEL SULFONAMIDE FIBRINOGEN RECEPTOR ANTAGONISTS

15

20 BACKGROUND OF THE INVENTION

The present invention provides novel compounds, novel compositions, methods of their use and methods of their manufacture, such compounds
25 being generally pharmacologically useful as anti-platelet aggregation agents in various vascular pathologies. The aforementioned pharmacologic activities are useful in the treatment of mammals. More specifically, the sulfonamide compounds of the
30 present invention act by blocking the molecular receptor site of the protein fibrinogen. Fibrinogen

This Sheet Has Been Replaced



is a glycoprotein that circulates in the blood plasma, and whose platelet receptor site is glycoprotein IIb/IIIa. By blocking the action of fibrinogen at the receptor (glycoprotein IIb/IIIa),
5 the compounds of the present invention interfere with platelet aggregation, which is a cause of many vascular pathologies. At the present time, there is a need in the area of vascular therapeutics for such a fibrinogen receptor blocking agent. By interfering
10 with hemostasis, such therapy would decrease the morbidity and mortality of thrombotic disease.

Hemostasis is the spontaneous process of stopping bleeding from damaged blood vessels. Precapillary vessels contract immediately when cut.
15 Within seconds, thrombocytes, or blood platelets, are bound to the exposed matrix of the injured vessel by a process called platelet adhesion. Platelets also stick to each other in a phenomenon known as platelet aggregation to form a platelet plug. This platelet
20 plug can stop bleeding quickly, but it must be reinforced by the protein fibrin for long-term effectiveness, until the blood vessel tear can be permanently repaired by growth of fibroblasts, which are specialized tissue repair cells.

25 An intravascular thrombus (clot) results from a pathological disturbance of hemostasis. The thrombus can grow to sufficient size to block off arterial blood vessels. Thrombi can also form in areas of stasis or slow blood flow in veins. Venous
30 thrombi can easily detach portions of themselves called emboli that travel through the circulatory system and can result in blockade of other vessels,

This Sheet Has Been Replaced



such as pulmonary arteries. Thus, arterial thrombi cause serious disease by local blockade, whereas venous thrombi do so primarily by distant blockade, or embolization. These diseases include venous
5 thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis and myocardial infarction, stroke, cerebral embolism, kidney embolisms and pulmonary embolisms.

There is a need in the area of
10 cardiovascular and cerebrovascular therapeutics for an agent which can be used in the prevention and treatment of thrombi, with minimal side effects, including unwanted prolongation of bleeding in other parts of the circulation while preventing or treating
15 target thrombi. The compounds of the present invention meet this need in the art by providing therapeutic agents for the prevention and treatment of thrombi.

The compounds of the present invention show
20 efficacy as antithrombotic agents by virtue of their ability to block fibrinogen from acting at its platelet receptor site and thus prevent platelet aggregation.

25

30


This Sheet Has Been Replaced

SUMMARY OF THE INVENTION

The present invention relates to novel compounds having the general structural formula I:

5

10



and the pharmaceutically acceptable salts thereof, wherein

15


R¹ is,

20

a four to eight member heterocyclic ring containing 1, 2, 3 or 4 heteroatoms wherein said hetero atoms are N, O or S and wherein said hetero ring is optionally substituted at any atom by H, R⁶ or R⁷; NR⁶R⁷



25



wherein R⁶ and R⁷ are independently hydrogen and unsubstituted or substituted C₀-₁₀ alkyl and cycloalkyl wherein said substituents are

30

C₁-₁₀ alkoxy,
C₁-₁₀ alkoxyalkyl,
C₁-₁₀ alkoxyalkyloxy,



- 5 C₁₋₁₀ alkoxy carbonyl,
C₁₋₁₀ alkyl carbonyl,
C₄₋₁₀ aralkyl carbonyl,
C₁₋₁₀ alkyl thiocarbonyl,
C₁₋₁₀ aralkyl thiocarbonyl,
thiocarbonyl,
C₁₋₁₀ alkoxy thiocarbonyl,
aryl,
a 5 to 6 membered saturated heterocyclic
10 ring containing 1,2,3 or 4 hetero atoms
wherein said heteroatoms are taken from the
group consisting of N, O and S,
- 15 C₁₋₄ alkanoylamino,
C₁₋₆ alkoxy carbonyl-C₀₋₆ alkylamino,
C₁₋₁₀ alkylsulfonylamino,
C₄₋₁₀ aralkylsulfonylamino,
C₄₋₁₀ aralkyl,
C₁₋₁₀ alkaryl,
20 C₁₋₁₀ alkylthio,
C₄₋₁₀ aralkylthio,
C₁₋₁₀ alkylsulfinyl,
C₄₋₁₀ aralkylsulfinyl,
C₁₋₁₀ alkylsulfonyl,
25 C₄₋₁₀ aralkylsulfonyl,
aminosulfonyl,
C₁₋₁₀ alkylaminosulfonyl,
C₄₋₁₀ aralkylsulfonylamino,
oxo,
30 thio,
unsubstituted and mono- and di-substituted
1-ethenyl, 2-ethenyl and 3-propenyl wherein

This Sheet Has Been Replaced



said substituents are selected from the group consisting of hydrogen, C₁₋₁₀ alkyl and C₄₋₁₀ aralkyl, carboxy, hydroxy, amino, C₁₋₆ alkylamino, C₁₋₆ dialkylamino, halogen, where halogen is defined as F, Cl, Br or I, nitro, and cyano,

and further wherein said N can additionally be substituted to form a quaternary ammonium ion wherein said substituent is as previously defined for R⁶ and R⁷;

R² and R³ are independently hydrogen, aryl and unsubstituted and substituted C₀₋₁₀ alkyl and cycloalkyl wherein said substituent is C₁₋₁₀ alkoxyalkyl, a 4 to 8 membered saturated heterocyclic ring system containing 1, 2, 3 or 4 heteroatoms, wherein said heteroatoms are taken from the group consisting of N, O and S, C₄₋₁₀ aralkyl, C₁₋₁₀ alkaryl, C₁₋₁₀ alkylthio,



- 5 C₄₋₁₀ aralkylthio,
C₁₋₁₀ alkylsulfinyl,
C₄₋₁₀ aralkylsulfinyl,
C₁₋₁₀ alkylsulfonyl,
C₄₋₁₀ aralkylsulfonyl,
carboxy,
C₁₋₁₀ alkylcarbonyl,
C₁₋₁₀ alkylthiocarbonyl,
C₄₋₁₀ aralkylcarbonyl,
10 C₄₋₁₀ aralkylthiocarbonyl,
C₁₋₆ alkoxycarbonyl,
C₄₋₁₀ aralkoxycarbonyl,
C₁₋₆ alkoxy,
C₁₋₆ alkoxycarbonyl-C₁₋₄ alkyl,
15 C₄₋₁₀ aralkoxycarbonyl-C₁₋₄ alkyl,
C₄₋₁₀ aralkoxy,
C₁₋₆ alkylamino,
C₁₋₁₂ dialkylamino,
C₁₋₆ alkanoylamino,
20 C₄₋₁₀ aralkanoylamino,
C₄₋₁₀ aralkylamino,

R⁴ is

- aryl,
25 C₁₋₁₀ alkyl or cycloalkyl,
C₄₋₁₀ aralkyl,
C₁₋₁₀ alkoxyalkyl,
C₁₋₁₀ alkaryl,
C₁₋₁₀ alkylthioalkyl,
30 C₁₋₁₀ alkoxythioalkyl,
C₁₋₁₀ alkylamino,
C₄₋₁₀ aralkylamino,


This Sheet Has Been Replaced



C₁₋₁₀ alkanoylamino,
C₄₋₁₀ aralkanoylamino
C₁₋₁₀ alkanoyl,
C₄₋₁₀ aralkanoyl, and
5 unsubstituted or substituted C₁₋₁₀ carboxyalkyl
wherein said substituent is aryl or C₁₋₁₀
aralkyl; further wherein any of the substituents
for R⁴ may be substituted by substituents
selected from the group as defined for R⁶;

10 R⁵ is

a four to eight member saturated or unsaturated
heterocyclic ring containing 1, 2, 3 or 4
15 heterocyclic atoms wherein said heteroatoms are
N, O and S and



20 $\begin{array}{c} \text{S} \\ \parallel \\ -\text{C}-\text{R}^8, \end{array}$ wherein R⁸ is

hydroxy,
C₁₋₁₀ alkyloxy,
25 C₁₋₁₀ alkaryloxy,
C₄₋₁₀ aralkyloxy,
C₄₋₁₀ aralkylcarbonyloxy,
C₁₋₁₀ alkoxyalkyloxy,
C₁₋₁₀ alkoxyalkylcarbonyloxy,
30 C₁₋₁₀ alkoxycarbonylalkyl,
C₁₋₁₀ alkylcarbonyloxyalkyloxy,
an L- or D-amino acid joined by an amide
linkage or




an L- or D-amino acid joined by an amide linkage and wherein the carboxylic acid moiety of said amino acid is esterified by C₁₋₆ alkyl or C₄₋₁₀ aralkyl,

5



10




wherein R⁹ and R¹⁰ are selected from the group consisting of hydrogen, C₁₋₁₀ alkyl and C₄₋₁₀ aralkyl;

15 X and Y are independently



20



25




a 4- to 8-membered ring containing 0,1,2,3, or 4 heteroatoms chosen from N, O and S, wherein said ring is independently substituted at any atom with R⁶,

30


aryl,





- 10 Z is an optional substituent that, when present, is independently chosen as defined for X and Y;
 m is an integer of from zero to ten;
 n is an integer of from zero to ten; and
 p is an integer of from zero to three.

- 15 A preferred group of compounds of the present invention are those defined for general structural formula II as:



wherein

R¹ is

- 30 a five to six member heterocyclic ring wherein said heteroatoms are N, O or S and wherein said heterocyclic ring is optionally substituted by



- C₁₋₅ alkyl; or
NR⁶R⁷ wherein R⁶ and R⁷ are independently
hydrogen,
unsubstituted or substituted C₁₋₁₀ alkyl
5 wherein said substituent is
C₁₋₁₀ alkoxy carbonyl,
aryl;
C₀₋₅ dialkylamino-C₁₋₁₀ alkyl,
C₄₋₁₀ aralkyl,
10 and further wherein said N can additionally be
substituted to form a quaternary ammonium ion wherein
said substituent is as previously defined for R⁶ and
R⁷;
15 R² and R³ are
hydrogen and
C₁₋₄ alkyl, C₄₋₁₀ aralkyl;
R⁴ is
20 aryl,
C₁₋₁₀ alkyl or cycloalkyl,
C₄₋₁₀ aralkyl,
C₁₋₁₀ alkoxyalkyl,
C₁₋₁₀ alkaryl,
25 unsubstituted or substituted C₁₋₁₀ carboxyalkyl
wherein said substituent is aryl, C₁₋₆ alkyl, or
C₄₋₁₀ aralkyl;
R¹¹ is
30 hydrogen or
C₁₋₁₀ alkyl;
X and Y are independently
aryl,



0, SO₂,

-CH=CH-; $\overset{\text{O}}{\underset{\text{N}}{\text{C}}}\text{NR}^6$ -; $\text{NR}^6\overset{\text{O}}{\underset{\text{N}}{\text{C}}}$ -; SO₂NR⁶-; or -NR⁶SO₂

5 a 5 or 6-membered ring containing 0,1 or 2 heteroatoms chosen from N or O;

Z is an optional substituent that, when present, is
0, SO₂, -NR⁶CO-, -CONR⁶-,

10 C₁₋₁₀ straight or branched alkyl;

m is an integer of from zero to eight;


n is an integer of from zero to two; and

p is an integer of from zero to two.

15

A more preferred group of compounds of the present invention are those defined for general structure formula III as

20



wherein

30

R¹ is

a five or six membered heterocyclic ring wherein said heteroatoms are N and O and wherein said heterocyclic ring is optionally substituted by C₁₋₅ alkyl;



NR⁶R⁷ wherein R⁶ and R⁷ are independently
C₁₋₁₀ alkyl, or
C₄₋₁₀ aralkyl
and further wherein said N can additionally be
5 substituted to form a quaternary ammonium ion wherein
said substituent is as previously defined for R⁶ and
R⁷;

R⁴ is
10 aryl,
C₁₋₁₀ alkyl or cycloalkyl, or
C₄₋₁₀ aralkyl;

X and Y are independently
15 phenyl
O, SO₂
 $\begin{array}{c} \text{O} \\ \parallel \\ \text{-CNR}^6\text{-} \end{array}; \quad \begin{array}{c} \text{O} \\ \parallel \\ \text{-NR}^6\text{C-} \end{array}$
or a 5- or 6- membered ring containing 0 or 1
20 heteroatoms chosen from N or O;

Z is an optional substituent that, when present, is
O, SO₂, -NR⁶CO-, -CONR⁶-, or -CH₂-; and

25 m is an integer of from zero to six.

DETAILED DESCRIPTION OF THE INVENTION

The term "pharmaceutically acceptable salts"
shall mean non-toxic salts of the compounds of this
30 invention which are generally prepared by reacting
the free base with a suitable organic or inorganic
acid. Representative salts include the following



salts:

	Acetate
	Benzenesulfonate
5	Benzoate
	Bicarbonate
	Bisulfate
	Bitartrate
	Borate
10	Bromide
	Calcium Edetate
	Camsylate
	Carbonate
	Chloride
15	Clavulanate
	Citrate
	Dihydrochloride
	Edetate
	Edisylate
20	Estolate
	Esylate
	Fumarate
	Gluceptate
	Gluconate
25	Glutamate
	Glycollylarsanilate
	Hexylresorcinate
	Hydrabamine
	Hydrobromide
30	Hydrochloride
	Hydroxynaphthoate
	Iodide



	Isothionate
	Lactate
	Lactobionate
	Laurate
5	Malate
	Maleate
	Mandelate
	Mesylate
	Methylbromide
10	Methylnitrate
	Methylsulfate
	Mucate
	Napsylate
	Nitrate
15	Oleate
	Oxalate
	Pamaote
	Palmitate
	Pantothenate
20	Phosphate/diphosphate
	Polygalacturonate
	Salicylate
	Stearate
	Subacetate
25	Succinate
	Tannate
	Tartrate
	Teoclate
	Tosylate
30	Triethiodide
	Valerate

This Sheet Has Been Replaced



The term "pharmacologically effective amount" shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical reponse of a tissue, system or animal that is being sought by a researcher or clinician. The term "anti-coagulant agent" shall include aspirin, heparin and warfarin. The term "fibrinolytic agent" shall include streptokinase and tissue plasminogen activator.

10 The term "aryl" shall mean a mono- or polycyclic ring system composed of 5- and 6- membered aromatic rings containing 0, 1, 2, 3, or 4 heteroatoms chosen from N, O, and S and either unsubstituted or substituted with R⁶.

15 The term "alkyl" shall mean straight or branched chain alkane, alkene or alkyne.

The term "alkoxy" shall be taken to include an alkyl portion where alkyl is as defined above.

The terms "aralkyl" and "alkaryl" shall be taken to include an alkyl portion where alkyl is as defined above and to include an aryl portion where aryl is as defined above.

The term "halogen" shall include fluorine, chlorine, iodine and bromine.

25 The term "oxo" shall mean the radical =O.

The term "thio" shall mean the radical =S.

Compounds of the invention may be administered to patients where prevention of thrombosis by inhibiting binding of fibrinogen to the platelet membrane glycoprotein complex IIb/IIIa receptor is desired. They are useful in surgery on peripheral arteries (arterial grafts, carotid



endarterectomy) and in cardiovascular surgery where manipulation of arteries and organs, and/or the interaction of platelets with artificial surfaces, leads to platelet aggregation and consumption. The
5 aggregated platelets may form thrombi and thromboemboli. They may be administered to these surgical patients to prevent the formation of thrombi and thromboemboli.

Extracorporeal circulation is routinely used
10 for cardiovascular surgery in order to oxygenate blood. Platelets adhere to surfaces of the extracorporeal circuit. Adhesion is dependent on the interaction between GPIIb/IIIa on the platelet membranes and fibrinogen adsorbed to the surface of
15 the circuit. (Gluszko et. al., Amer. J. Physiol., 1987, 252:H, pp 615-621). Platelets released from artificial surfaces show impaired hemostatic function. Compounds of the invention may be administered to prevent adhesion.

20 Other application of these compounds include prevention of platelet thrombosis, thromboembolism and reocclusion during and after thrombolytic therapy and prevention of platelet thrombosis, thromboembolism and reocclusion after angioplasty of
25 coronary and other arteries and after coronary artery bypass procedures. They may also be used to prevent myocardial infarction.

The compounds of the present invention can be administered in such oral dosage forms as tablets,
30 capsules, pills, powders, granules, elixers, tinctures, suspensions, syrups and emulsions. Likewise, they may also be administered in



intravenous, intraperitoneal, subcutaneous or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound
5 desired can be employed as an anti-aggregation agent.

The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the
10 patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and
15 prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.

Oral dosages of the present invention, when used for the indicated effects, will range between
20 about 0.01 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day and preferably 1.0-100 mg/kg/day and most preferably 1.0 to 50 mg/kg/day. Intravenously, the most preferred doses will range from about 1 to about 10 mg/kg/minute
25 during a constant rate infusion. Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore,
30 preferred compounds for the present invention can be

This Sheet Has Been Replaced



administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art.

- 5 To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

In the methods of the present invention, the
10 compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as 'carrier' materials) suitably selected with
15 respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.

For instance, for oral administration in the
20 form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium
25 sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover,
30 when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable



binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and



polyglycolic acid, polyepsilon caprolactone,
polyhydroxy butyric acid, polyorthoesters,
polyacetals, polydihydropyrans, polycyanoacrylates
and cross-linked or amphipathic block copolymers of
5 hydrogels.

The compounds of the present invention can
also be co-administered with suitable anti-coagulant
agents or thrombolytic agents to achieve synergistic
effects in the treatment of various vascular
10 pathologies.

The compounds of formula I can be prepared
readily according to the following reaction Schemes
and Examples or modifications thereof using readily
available starting materials, reagents and
15 conventional synthesis procedures. In these
reactions, it is also possible to make use of
variants which are themselves known to those of
ordinary skill in this art, but are not mentioned in
greater detail.

20 The most preferred compounds of the
invention are any or all of those specifically set
forth in these examples. These compounds are not,
however, to be construed as forming the only genus
that is considered as the invention, and any
25 combination of the compounds or their moieties may
itself form a genus. The following examples further
illustrate details for the preparation of the
compounds of the present invention. Those skilled in
the art will readily understand that known variations
30 of the conditions and processes of the following
preparative procedures can be used to prepare these
compounds. All temperatures are degrees Celsius




unless noted otherwise.

Reagent symbols have the following meanings:

	BOC:	t-butyloxycarbonyl
	Pd-C:	Palladium on activated carbon
5		catalyst
	DMF:	Dimethylformamide
	DMSO:	Dimethylsulfoxide
	CBZ:	Carbobenzyloxy
	CH ₂ Cl ₂ :	Methylene chloride
10	CHCl ₃ :	Chloroform
	EtOH:	Ethanol
	MeOH:	Methanol
	EtOAc:	Ethyl acetate
	HOAc:	Acetic acid
15	THF:	Tetrahydrofuran


The source for the following compounds is as shown:

20



25 is described below.

30



2-(4-N-t-Butyloxycarbonylpiperidinyl)ethanol

This Sheet Has Been Replaced




4-Piperidine-2-ethanol (Available from Aldrich) (130 g, 1.0 mole) was dissolved in 700 mL dioxane, cooled to 0° C and treated with 3 N NaOH (336 mL, 1.0 mole), and di-*t*-butylcarbonate (221.8 g, 1.0 mole). The ice bath was removed and the reaction stirred overnight. The reaction was concentrated, diluted with water and extracted with ether. The ether layers were combined, washed with brine, dried over MgSO₄, filtered and evaporated to give 225.8 g of product (98%).

R_f = 0.37 in 1:1 EtOAc/Hexanes, ninhydrin stain

¹H NMR (300MHz, CDCl₃) δ 4.07 (bs, 2H), 3.7 (bs, 2H), 2.7 (t, J = 12.5 Hz, 2H), 1.8-1.6 (m, 6H), 1.51 (s, 9H), 1.1 (ddd, J = 4.3, 12.5, 12 Hz, 2H).

20

25



Methyl 4-(4-*N*-*t*-butyloxycarbonylpiperidinyl)-but-2-enoate

30

Oxalyl chloride (55.8 mL, 0.64 mole) was dissolved in 1 L CH₂Cl₂ and cooled to -78° C under





N₂. DMSO (54.2 mL, 0.76 mole) was added dropwise. After gas evolution had ceased, 2-(4-N-t-butyloxy-carbonylpiperidinyloxy)ethanol (102.5 g, 0.45 mole) dissolved in 200 mL CH₂Cl₂ was added over 20 minutes. After stirring an additional 20 minutes, triethylamine (213 mL, 1.53 mole) was added dropwise and the cold bath removed. After 1 and 1/2 hours TLC showed starting material gone. Carbomethoxytri-phenylphosphorane (179 g, 0.536 mole) was added and the reaction stirred overnight. The solution was diluted with 300 mL Et₂O, extracted once with 800 mL H₂O, twice with 300 mL 10% KHSO₄ solution, then once with 300 mL brine. The organic layer was dried over MgSO₄, filtered and evaporated. Column chromatography (SiO₂, 5% EtOAc/Hexanes) yielded 78.4 g (62%) of pure methyl 4-(4-N-t-butyloxy-carbonylpiperidinyloxy) but-2-enoate. ¹H NMR (300MHz, CDCl₃) δ 6.9 (ddd J = 15.6, 7.6, 7.6 Hz, 1H), 5.8 (d, J = 15.6 Hz, 1H), 4.0 (bs, 2H), 3.7 (s, 3H), 2.6 (t, J = 12.6 Hz, 2H), 2.1 (t, J = 7.4 Hz, 2H), 1.7-1.4 (m, 3H), 1.4 (s, 9H), 1.1 (m, 2H).

25

1. H₂/Pd on C

2. NaOH

3. BH₃4. (C₆H₅)₃P, CBr₄

30

This Sheet Has Been Replaced



4-(4-N-t-Butyloxycarbonylpiperidinyl)butyl bromide
Methyl 4-(4-N-t-butyloxycarbonylpiperidin-
yl)but-2-enoate (36.2 g, 0.128 mole), was dissolved
in 500 mL EtOAc. 10% Palladium on carbon (10 g) was
5 added as a slurry in EtOAc and the reaction was
placed under H_2 (in a balloon) overnight. The
reaction was filtered through Solka-Floc, the cake
washed with EtOAc and the ethyl acetate evaporated to
give 34.7 g (90%) of methyl 4-(4-N-t-butyloxycarbonyl-
10 piperidin-4-yl)butanoate. TLC R_f = 0.69 in 30%
EtOAc/Hexanes.

1H NMR (300MHz, $CDCl_3$) δ 4.0 (bs, 2H), 3.6 (s, 3H),
2.60 (t, J = 12.3 Hz, 2H), 2.20 (t, J = 7.4, 2H), 1.6
15 (m, 4H), 1.40 (s, 9H), 1.40 (m, 1H), 1.20 (m, 2H),
1.0 (m, 2H).

The butanoate ester (45.3 g, 0.159 mole)
was dissolved in CH_3OH and treated with 1 N NaOH (500
20 mL, 0.5 mole) overnight. The solvent was removed in
vacuo, water was added and the solution washed with
ether, then acidified with 10% $KHSO_4$ solution. The
aqueous layer was washed with ether, the ether layers
were combined, washed with brine, dried ($MgSO_4$), and
25 concentrated to give the corresponding acid as a
clear oil (41.85 g, 97% yield).

1H NMR (300MHz, $CDCl_3$) δ 4.0 (bs, 2H), 2.6 (m, 2H),
2.25 (m, 2H), 1.6 (bs, 4H), 1.4 (s, 9H), 1.3-0.9 (9H).
30

This acid (20.4 g, 0.077 mole) was treated
with borane (BH_3/THF , 235 mL, 235 mmole) in THF at 0°



for 1 hour. NaOH (1N, 250 mL) was added dropwise and the solution stirred overnight. The resulting reaction mixture was concentrated to remove THF and extracted with ether. The ether extracts were
5 combined, dried over MgSO_4 , filtered and evaporated to give the corresponding alcohol as 19.7 g of a colorless oil.

$R_f = 0.7$ in 2:1 ethyl acetate/hexanes.

10

^1H NMR (300MHz, CDCl_3) δ 4.1 (bs, 2H), 3.6 (t, 2H), 2.65 (t, 2H), 2.1 (bs, 1H), 1.65 (bs, 2H), 1.55 (m, 2H), 1.4 (s, 9H), 1.35 (m, 3H), 1.25 (m, 2H), 1.1 (m, 2H).

15

This alcohol (19.7 g, 76.5 mmole) was dissolved in THF and treated with triphenylphosphine (23.1 g, 88 mmole) and cooled to 0° C. Carbon tetrabromide (29.8 g, 89.9 mmol) was added in one
20 portion, the cold bath was removed and the reaction stirred overnight. Additional triphenyl phosphine (11.71 g) and carbon tetrabromide (14.9 g) was added to drive the reaction to completion. The mixture was filtered and the liquid was diluted with ether and
25 filtered again. After solvent removal the resulting liquid was adsorbed onto SiO_2 and chromatographed with 5% EtOAc/Hexanes to yield 4-(4-N-t-butyloxy-carbonylpiperidin-4-yl)butyl bromide as a clear colorless oil (20.7 g, 85% yield).

30


$R_f = 0.6$ in 1:4 ethyl acetate/hexanes



^1H NMR (300MHz, CDCl_3) δ 4.1 (bs, 2H), 3.4 (t, 2H), 2.65 (t, 2H), 1.85 (m, 2H), 1.65 (bd, 2H), 1.4 (s, 9H), 1.35 (m, 2H), 1.3 (m, 3H), 1.1 (m, 2H).


- 5 2.BocNH(CH₂)₆Br Commercial H₂N(CH₂)₅CH₂OH was protected as the N-Boc derivative in standard fashion and this was converted to the bromide with Ph₃P/CBr₄ in THF. Utilization of starting amino alcohols of varying chain lengths provides the analogous halides in this manner.

15



Purchased from Sigma.

20



HN OH (Aldrich) was N-Boc protected in the standard manner.

25




HN OH was N-Cbz protected in the standard fashion and converted to final product as described in US Serial No. 589,145.

30


This Sheet Has Been Replaced

SCHEME 1

5




10



15





20



25



30




1-5


This Sheet Has Been Replaced




5



10



15



20


25

30

This Sheet Has Been Replaced



EXAMPLE 1



10


2-S-(Benzyloxycarbonylamino)-3-[4-(N-t-butyloxy-
carbonylpiperidin-4-yl)butyloxyphenyl]propionic
acid (1-2)

15 N-CBZ-L-tyrosine (1-1) (17.58 g, 0.055
mmole) was dissolved in DMF (75 mL), cooled to 0-10°
C and treated with sodium hydride (2.88 g, 0.12
mole). This suspension was stirred at 0-10° C for 1
hour and then N-t-butyloxycarbonylpiperidin-4-
20 ylbutyl bromide (17.70 g, 0.055 mole) in 25 mL DMF
was added dropwise over 15 minutes. The reaction
mixture was then stirred at room temperature for 16
hours. The solvent was removed in vacuo and the
residue was taken up in a mixture of 500 mL EtOAc/100
25 mL 10% KHSO₄. The organic phase was washed with
brine, dried (Na₂SO₄) and the solvent was removed to
give a viscous oil. This was purified by flash
chromatography on silica gel eluting with 98:2:0.5
CHCl₃/CH₃OH/HOAc to give pure 1-2 (23.75 g), R_f =
30 0.35, as a pale yellow oil.

¹H NMR (300MHz, CDCl₃) δ 1.00-1.15 (2H, m), 1.20-1.80
(16H, m), 2.62 (2H, t), 3.10 (2H, m), 3.91 (2H, t),
4.04 (2H, m), 5.10 (2H, m), 5.22 (1H, d), 6.78 (2,
d), 7.04 (2H, d), 7.35 (5H, m).



EXAMPLE 2




Methyl 2-S-(Benzyloxycarbonylamino)-3-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]-
15 propionic acid (1-3)

1-2 (10.05 g, 18.1 mmole) was dissolved in CH₃OH (150 mL) at room temperature and cesium carbonate (2.95 g, 9.06 mmole) was added and the resulting mixture stirred for 15 minutes to give a clear solution. The CH₃OH was removed at reduced
20 pressure and the residue was then dissolved in DMF (150 mL) and treated dropwise with methyl iodide (2.57 g, 18.1 mmole). The resulting solution was stirred overnight at room temperature. The solvent
25 was removed in vacuo and the residue was taken up in 400 mL ether and washed with 3 x 50 mL portions of H₂O, 50 mL brine and dried (Na₂SO₄). Solvent removal provided 1-3 as an oil.

¹H NMR (300 MHz, CDCl₃) δ 1.0-1.15 (2H, m), 1.30-1.70 (16H, m), 2.68 (2H, dt), 3.05 (2H, m), 3.72 (3H, s),
30 3.91 (2H, t), 4.08 (2H, d), 4.61 (1H, m), 5.10 (2H, m), 5.18 (1H, m), 6.79 (2H, d), 6.98 (2H, d), 7.35 (5H, m).



EXAMPLE 3



10

Methyl 2-S-Amino-3-[4-(N-t-butyloxycarbonylpiperidin-4-yl)-butyloxyphenyl]propionate (1-4)

15 To 1-3 (5.0 g, 8.79 mmole) dissolved in absolute ethanol (150 mL) was added 10% Pd/C (0.5 g) and the resulting suspension was hydrogenated under balloon pressure for 12 hours. The catalyst was then filtered off and the solvent was removed in vacuo to

20 give 1-4 (3.6 g) as an oil.

¹H NMR (300 MHz, CDCl₃) δ 1.00-1.20 (2H, m), 1.22-1.55 (12H, m), 1.60-1.75 (4H, m), 2.00 (2H, bs), 2.68 (2H, t), 2.87 (1H, dd), 3.05 (1H, dd), 3.72 (3H, s), 3.93 (2H, t), 4.09 (2H, m), 6.82 (2H, d), 7.10 (2H, d).


25

30

This Sheet Has Been Replaced



EXAMPLE 4



Methyl 2-S-(n-Butylsulfonylamino)-3-[4-(N-t-butylloxycarbonylpiperidin-4-yl)butyloxyphenyl]-propionate (1-8)


20 1-4 (0.59 g, 1.36 mmole) was dissolved in ethyl acetate (10 mL) and NaHCO_3 (0.7 g, 8.68 mmole) was added with stirring at room temperature followed by butanesulfonyl chloride (0.36 mL, 2.76 mmole) and the resulting mixture was refluxed for 26 hours. The

25 cooled reaction mixture was filtered and concentrated and the residue was purified by flash chromatography on silica gel eluting with 4:1 hexane/EtOAc to give pure 1-8 (0.305 g) $R_f = 0.7$ in 1:1 hexane/EtOAc, ninhydrin stain.

30 ^1H NMR (300 MHz, CDCl_3) δ 0.82 (3H, t), 1.05 (2H, ddd), 1.45 (9H, s), 1.1-1.6 (1H, m), 1.7 (4H, m), 2.6 (2H, t), 2.6-2.8 (2H, m), 2.78 (1H, dd), 3.05 (1H, dd), 3.7 (3H, s), 3.93 (2H, t), 4.05 (2H, bd), 4.15 (1H, dd), 6.85 (2H, d), 7.15 (2H, d).



EXAMPLE 5



2-S-(n-Butylsulfonylamino)-3[4-(piperidin-4-yl)butyl-
oxyphenyl]propionic acid hydrochloride (1-9)

15 1-8 (0.325 g, 0.59 mmole) was dissolved in
1:1:1 CH₃OH/H₂O/THF and LiOH•H₂O (0.157g, 3.76 mmole)
was added. The resulting solution was stirred at
room temperature for 3 hours, then concentrated,
diluted with 10% KHSO₄ and extracted with EtOAc.
20 This provided 2-S-(n-butylsulfonylamino)-3[4-
(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]-
propionic acid. This acid (0.315 g, 0.59 mmole) was
dissolved in EtOAc (20 mL) and treated with HCl gas
at -20° C for 15 minutes. The reaction mixture was
25 then stoppered and was stirred at -5° C for 1 hour at
which time all starting material was consumed. Argon
gas was bubbled through the reaction mixture for 15
minutes and the solvent was removed to give a residue
that was triturated with ether to provide pure 1-9
30 (0.29 g) as a pale yellow solid.




^1H NMR (300 MHz, CD_3OD) δ 0.85 (3H, t), 1.2 (2H, dd), 1.2-1.7 (9H, m), 1.7 (2H, m), 1.95 (2H, bs), 2.65 (2H, t), 2.8 (1H, dd), 2.95 (2H, bt), 3.10 (1H, dd), 3.83 (2H, bs), 3.95 (2H, t), 4.1 (1H, dd), 6.85 (2H, d), 7.2 (2H, d).

Analysis for $\text{C}_{22}\text{H}_{36}\text{N}_2\text{O}_5\cdot\text{HCl}\cdot 0.8 \text{ H}_2\text{O}$

Calculated: C = 53.76, H = 7.92, N = 5.70

10 Found: C = 53.76, H = 7.66, N = 5.44.

EXAMPLE 6



25 Methyl 2-S-(Benzylsulfonylamino)-3-[4-(N-t-butyloxy-carbonylpiperidin-4-yl)butyloxyphenyl]propionate (1-10)

1-4 (0.59g, 1.36 mmole) was treated with benzylsulfonyl chloride (0.263 g, 1.38 mmole) as described above for 1-8. The crude reaction product was purified by flash chromatography on silica gel eluting with 3:1 hexane/EtOAc to give pure 1-10 (0.35 g) as an oil.

30




^1H NMR (300 MHz, CD_3OD) δ 0.85-1.10 (2H, m),
1.10-1.23 (2H, m), 1.35-1.52 (11H, m), 1.61-1.80 (4H,
m), 2.65-3.00 (4H, m), 3.65 (3H, s), 3.90-4.14 (5H,
5 m), 6.85 (2H, d), 7.08 (2H, d), 7.22 (2H, m), 7.30
(3H, m).

EXAMPLE 7

10

15



2-S-(Benzylsulfonylamino)-3-[4-(piperidin-4-yl)butyl-
20 oxyphenyl]propionic acid hydrochloride (1-11)


Treatment of 1-10 (0.354 g, 0.60 mmole)
with LiOH (0.15 g, 3.7 mmole) as described for 1-8
gave 2-S-(benzylsulfonylamino)-3-[4-(N-t-butyloxy-
carbonylpiperidin-4-yl)butyloxyphenyl]propionic acid
25 (0.35 g) as a viscous oil.

^1H NMR (300MHz CD_3OD) δ 0.84-1.06 (3H, m), 1.23 (4H,
m), 1.34-1.50 (11H, m), 1.60-1.78 (5H, m), 2.65 (2H,
bt), 2.82 (1H, m), 3.02 (1H, m), 3.91 (2H, m),
30 3.96-4.12 (5H, m), 6.83 (2H, d), 7.15 (2H, d), 7.22
(2H, m), 7.29 (3H, m).



This acid (0.35 g, 0.60 mmole) was dissolved in 20 mL EtOAc and treated with HCl gas as described for 1-9 to give pure 1-11 as a white solid (0.30 g).

¹H NMR (300MHz, CD₃OD) δ 1.32 (4H, m), 1.40-1.65 (3H, m), 1.72 (2H, m), 1.92 (2H, d), 2.77-3.08 (4H, m), 3.33 (3H, m), 3.95-4.14 (5H, m), 6.86 (2H, d), 7.17 (2H, d), 7.28 (2H, m), 7.31 (3H, m).



Methyl 2-S-(2-Styrylsulfonylamino)-3-[4-(N-t-butyl-oxycarbonylpiperidin-4-yl)butyloxyphenyl]propionate (1-12)

1-4 (0.647 g, 15 mmoles) was dissolved in ethyl acetate (20 ml), and NaHCO₃ (0.454 g, 5.4 mmoles) was added followed by β-styrenesulfonyl chloride (0.365 g, 18.0 mmoles) and the resulting reaction mixture was heated at reflux with stirring

This Sheet Has Been Replaced



for 16 hours. The cooled reaction mixture was filtered, the solvent removed and the residue was purified by flash chromatography on silica gel eluting with hexane (3)/ethyl acetate (1) to give pure 1-12.

5

^1H NMR (300 MHz, CDCl_3) δ 1.10 (2H, m), 1.30-1.55 (14 H, m), 1.65-1.80 (4H, m), 2.68 (2H, t), 3.01 (2H, dt), 3.62 (3H, s), 3.88 (2H, t), 4.09 (2H, m), 4.22 (1H, m), 4.98 (1H, d), 6.45 (1H, d), 6.80 (2H, d), 7.06 (2H, d), 7.40 (4H, s).

10

2-S-(2-Styrylsulfonylamino)-3-4-[4-piperidinylbutyl-oxyphenyl] propionic acid hydrochloride (1-13)

1-12 (0.58 g, 0.97 mmole) was dissolved in THF(1)- H_2O (1)-MeOH(1) (15 ml) and lithium hydroxide (0.12 g, 5.0 mmole) was added and the resulting clear solution was stirred overnight at room temperature.

The reaction mixture was diluted with 75 ml H_2O , acidified to pH 2-3 with 10% KHSO_4 solution and then extracted with 3 x 50 ml EtOAc. The organic extract was dried, the solvent removed, and the residue purified by flash chromatography on silica gel eluting with CHCl_3 (97)-MeOH(3)-HOAc(1) to give the desired acid ($R_f=0.2$).


25 This acid was dissolved in EtOAc and treated with HCl gas as described for 1-9 to give 1-13.

^1H NMR (300 MHz, CD_3OD) δ 1.15-1.70 (10H, m), 1.70-1.82 (2H, t), 1.97 (2H, t), 2.78-3.12 (5H, m), 3.35 (3H, m), 3.87 (2H, t), 4.03 (1H, m), 6.50 (1H, d), 6.69 (2H, m), 7.18 (3H, m), 7.41 (5H, bs).

30



5



10

15

20 2-S-(2-Phenethylsulfonylamino)-3-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]propionic acid
(1-14)

1-12a (0.21 g) was dissolved in 20 ml absolute ethanol, 0.1 g 10% Pd/C was added and the stirred suspension was hydrogenated under balloon pressure. After 4 hours the reaction was stopped and the solvent was removed to give the desired product 1-14 (0.194 g).

¹H NMR (300 MHz, CD₃OD) δ 1.05 (2H, m), 1.30-1.40 (3H, m), 1.47 (14H, m), 1.72 (5H, m), 2.67-2.93 (8H, m), 3.13 (1H, m), 3.31 (2H, m), 3.82 (2H, m), 4.00-4.20 (4H, m), 6.82 (2H, d), 7.07 (2H, d), 7.21 (5H, m).



2-S-(2-Phenethylsulfonylamino)-3-4-[4-piperidinyl-
butyloxyphenyl]propionic acid hydrochloride (1-15)

1-14 (0.194 g) was dissolved in EtOAc and
treated with HCl gas as described for 1-9 to provide
5 pure 1-15 (0.145 g).

^1H NMR (300 MHz, CD_3OD) δ 1.25-1.68 (8H, m), 1.73
(2H, m), 1.93 (2H, m), 2.78 (3H, m), 2.91 (4H, m),
3.13 (1H, m), 3.33 (4H, m), 3.86 (2H, m), 4.18 (1H,
m), 6.80 (2H, d), 7.09 (2H, d), 7.22 (5H, m).


10

15

20

25

30



This Sheet Has Been Replaced



Methyl 2-S-(Phenylsulfonylamino)-3-[4-(N-t-butyloxy-carbonylpiperidin-4-yl)butyloxyphenyl]propionate (1-16).

- 1-4 (0.647 g, 1.5 mmoles) was treated with
5 phenylsulfonyl chloride (0.318 g, 1.8 mmoles) as described for 1-8. The crude product was purified by flash chromatography on silica gel eluting with CHCl_3 (98)-MeOH(2) to give pure 1-16 (0.67 g).
 ^1H NMR (300 MHz, CDCl_3) δ 1.09 (2H, m), 1.25-1.40
10 (3H, m), 1.42 (9H, bs), 1.60-1.85 (6H, m), 2.66 (2H, m), 2.96 (2H, d), 3.55 (3H, s), 3.89 (2H, t), 4.09 (4H, m), 5.12 (1H, d), 6.72 (2H, d), 6.95 (2H, d), 7.40-7.65 (3H, m), 7.75 (2H, m).

- 15 2-S-(Phenylsulfonylamino)-3-(4-piperidin-4-ylbutyloxy-phenyl)propionic acid hydrochloride (1-17).
-

- 1-16 (0.525 g) was treated with lithium hydroxide as described for 1-8 to give crude product that was purified by flash chromatography on silica
20 gel eluting with CHCl_3 (97)-MeOH(3)-HOAc(1) to provide pure acid ($R_f \approx 0.2$).


This acid was treated with HCl gas in EtOAc as described for 1-9 to provide pure 1-17.

- 25 ^1H NMR (300 MHz, CD_3OD) δ 1.28-1.47 (6H, m), 1.50-1.70 (3H, m), 1.75 (2H, m), 1.97 (2H, d), 2.77 (1H, m), 2.95 (3H, m), 3.35 (4H, m), 3.93 (3H, m), 6.72 (2H, d), 7.02 (2H, d), 7.41 (2H, m), 7.52 (1H, m), 7.67 (2H, m).

30



5



10

Methyl 2-S-(2-Thienylsulfonylamino)-3-[4-(N-t-butyl-oxycarbonylpiperidin-4-yl)butyloxyphenyl]propionate

15 (1-18).

1-4 (0.304 g, 0.7 mmoles) was treated with 2-thienylsulfonyl chloride (0.155 g, 0.85 mmoles) as described for 1-8 to provide crude product. This was purified by flash chromatography on silica gel eluting with CHCl_3 (98)- CH_3OH (2) to afford pure 1-18 as a viscous oil, R_f 0.3 [silica gel, CHCl_3 (98)- CH_3OH (2)]

^1H NMR (300 MHz, CDCl_3) δ 1.10 (2H, m), 1.31 (4H, m), 1.36-1.80 (16 H, m), 2.68 (2H, bt), 3.03 (2H, d), 3.57 (3H, s), 3.91 (2H, t), 4.08 (2H, m), 4.29 (1H, m), 5.16 (1H, d), 6.78 (2H, d), 7.00 (4H, m), 7.55 (2H, dd).

30

This Sheet Has Been Replaced



2-S-(2-Thienylsulfonylamino)-3-[4-(piperidin-4-yl)-
butyloxyphenyl]propionic acid hydrochloride (1-19).

Treatment of 1-18 (0.22 g, 0.38 mmoles) with
5 LiOH (0.045 g, 1.89 mmoles) as described for 1-8
provided the desired acid, which was purified by
flash chromatography on silica gel eluting with
CHCl₃(97)-CH₃OH(3)-HOAc(1).

10 ¹H NMR (300 MHz, CD₃OD) δ 1.05 (2H, d t), 1.20-1.40
(5H, m), 1.40-1.60 (12H, m) 1.65-1.80 (5H, m),
2.65-2.82 (4H, m), 2.98 (1H, dd), 3.30 (1H, m), 3.92
(2H, t), 4.00-4.13 (5H, m), 6.75 (2H, d), 7.02 (3H,
m), 7.39 (1H, d), 7.67 (1H, d).

15

Treatment of this acid with HCl gas as
described for 1-9 provided 1-19 as a white solid
after trituration.

20 Analysis Calcd. for C₂₂H₃₀N₂O₅S₂•HCl•0.5 H₂O:

C, 51.60, H, 6.30, N, 5.47.

Found: C, 51.57, H, 6.20, N, 5.51.


¹H NMR (300 MHz, CD₃OD) δ 1.29-1.45 (4H, m),
25 1.47-1.70 (3H, m), 1.71-1.83 (2H, m), 1.91-2.00 (2H,
bd), 2.79 (1H, m), 2.90-3.04 (3H, m), 3.95 (2H, t),
4.04 (1H, m), 6.76 (2H, d), 7.05 (3H, m), 7.40 (1H,
m), 7.79 (1H, m).

30

This Sheet Has Been Replaced



5



10

15

2-S-(Dansylamino)-3-[4-(N-t-butyloxycarbonyl-piperidin-4-yl)butyloxyphenyl]propionate (**1-20**).

20

1-4 (0.304 g, 0.7 mmol) was treated with dansyl chloride (0.208 g, 0.77 mmol) as described for **1-8** to provide crude product which was purified by flash chromatography on silica gel eluting with hexane(75)-EtOAc(25) to give pure **1-20**. R_f 0.25 (silica gel eluting with hexane(75)-EtOAc(25)).

25

1H NMR (300 MHz, $CDCl_3$) δ 1.10 (2H, m), 1.21-1.38 (6H, m), 1.40-1.53 (11H, m), 1.60-1.80 (6H, m), 2.68 (2H, bt), 2.89 (6H, s), 3.33 (2H, s), 3.89 (2H, t), 4.05-4.19 (4H, m), 5.24 (1H, m), 6.62 (2H, d), 6.82 (2H, d), 7.18 (1H, d), 7.50 (2H, m), 8.19 (2H, t), 8.51 (1H, d).

30

This Sheet Has Been Replaced



2-S-(Dansylamino)-3-[4-(piperidin-4-yl)butyloxy-
phenyl]propionic acid hydrochloride (1-21).

Treatment of 1-20 (0.275 g, 0.412 mmoles)
with LiOH as described for 1-8 gave the desired acid
5 as a highly fluorescent viscous residue.

^1H NMR (300 MHz, CD_3OD) δ 1.09 (2H, m), 1.22-1.40
(3H, m), 1.40-1.57 (12H, m), 1.65-1.80 (3H, m),
2.60-2.80 (3H, m), 2.90 (6H, s), 3.31 (3H, m), 3.80
10 (2H, t), 3.90 (1H, m), 4.01-4.15 (4H, m), 6.47 (2H,
d), 7.21 (1H, d), 7.42 (2H, m), 7.98 (1H, d), 8.20
(1H, d), 8.46 (1H, d).

Treatment of this acid in EtOAc with HCl gas
15 as described for 1-9 provided 1-21 as a white solid
upon ethylacetate trituration.

Analysis for $\text{C}_{30}\text{H}_{39}\text{N}_3\text{O}_5\text{S} \cdot 1.8 \text{ HCl} \cdot \text{H}_2\text{O}$:


C, 56.53; H, 6.77; N, 6.59; Cl, 10.01.

20 Found: C, 56.48; H, 6.66; N, 6.36; Cl, 10.21.

^1H NMR (300 MHz, CD_3OD) δ 1.30-1.51 (7H, m),
1.52-1.80 (4H, m), 1.95 (2H, bt), 2.65 (1H, m),
2.95 (3H, m), 3.30-3.40 (4H, m), 3.45 (6H, s),
25 3.84-3.97 (3H, m), 6.45 (2H, d), 6.77 (2H, d),
7.71 (2H, m), 8.00 (1H, d), 8.16 (2H, d), 8.55
(1H, d), 8.70 (1H, d).



SCHEME 2



30

25


20

15


10

5

This Sheet Has Been Replaced



EXAMPLE 8



10

2-S-(Benzyloxycarbonylamino)-3-[4-(6-N-t-butyloxy-carbonylaminohexyloxy)phenyl]propionic acid (2-1)

15 N-CBZ-L-tyrosine (15.0 g, 0.045 mole) was dissolved in 75 mL DMF and added at 0-10° C to a suspension of sodium hydride (2.16 g, 0.09 mole) in 25 mL DMF. The resulting suspension was stirred at 0-10° C for 1.0 hour and then 6-(t-butyloxycarbonyl-amino)hexyl bromide (12.6 g, 0.045 mole) in 25 mL DMF
20 was added dropwise at 0-5° C and the clear, dark reaction mixture was stirred at room temperature overnight.


After solvent removal, the residue was taken
25 up in EtOAc and this was made acidic with 10% KHSO₄ solution. The organic phase was separated, washed with brine, dried (Na₂SO₄) and the solvent removed to give an oil. This was purified by column chromatography on silica gel eluting with 98:2:1
30 CHCl₃/CH₃OH/HOAc to give pure 2-1 as a clear oil.

¹H NMR (300 MHz, CD₃OD) δ 1.45 (15H, m), 1.75 (2H, m), 2.80-3.15 (6H, m), 3.91 (2H, t), 4.38 (1H, m), 4.95 (6H, m), 6.85 (2H, d), 7.06 (2H, d)



EXAMPLE 9

5



10

Methyl 2-S-(Benzyloxycarbonylamino)-3-[4-(6-N-t-butyl
butyloxycarbonylaminohexyloxy)phenyl]propionate (2-2)

15 Compound 2-1 (10.0 g, 19.43 mmole) in 75 mL DMF was treated with cesium carbonate (3.16 g, 9.72 mmole) with stirring at room temperature for 1.9 hours. Then, methyl iodide (2.76 g, 19.43 mmole) was added dropwise and the reaction mixture was stirred
20 overnight at ambient temperature. The solvent was removed at high vacuum (30° C) and the residue was taken up in 300 mL EtOAc and washed with 2 x 40 mL portions of saturated NaHCO₃ solution, brine and dried (Na₂SO₄). Solvent removal provided 2-2 (8.5 g,
25 83%) as a clear oil.


¹H NMR (300MHz, CDCl₃) δ 1.25-1.53 (16H, m), 1.76 (2H, m), 2.96-3.17 (4H, m), 3.71 (3H, s), 3.90 (2H, t), 4.61 (1H, m), 5.10 (2H, m), 5.19 (1H, m), 6.88
30 (2H, d), 6.98 (2H, d), 7.32 (5H, m).

This Sheet Has Been Replaced



EXAMPLE 10

5



10

Methyl 2-S-Amino-3-[4-(6-N-t-butyloxycarbonyl-
aminohexyloxy)phenyl]propionate (2-3)

15

Compound 2-2 (8.0 g, 15.1 mmole) was dissolved in 150 mL absolute ethanol and 1.0 g 10% Pd/ C was added. This suspension was hydrogenated in a Parr apparatus (50 psi) for 3.5 hours. The catalyst was then filtered off and the solvent removed on the rotary evaporator to give pure 2-3 (5.56 g) as a clear oil. $R_f = 0.4$ on SiO_2 with 95:5 $CHCl_3/CH_3OH$

20

1H NMR (300 MHz, $CDCl_3$) δ 1.30-1.55 (16H, m), 1.70 (2H, m), 2.80 (1H, m), 3.00-3.17 (3H, m), 3.71 (3H, s), 3.93 (2H, t), 6.82 (2H, d), 7.09 (2H, d).

25


30

This Sheet Has Been Replaced



EXAMPLE 11

5



10

2-S-(Methylsulfonylamino)-3-[4-(6-N-t-butyloxy-
15 carbonylaminohexyloxy)phenyl]propionate (2-4)

2-3 (0.40 g, 1.01 mmole) was treated with
methanesulfonyl chloride (0.116 g, 1.01 mmole) and
NaHCO₃ (0.25 g, 3.0 mmole) as described for 1-8. The
crude reaction product was purified by flash
20 chromatography on silica gel eluting with 30% EtOAc
/hexanes to give pure 2-4 (0.10g) as a clear oil.

¹H NMR (300MHz, CDCl₃) δ 1.36-1.56 (15H, m), 1.77
(2H, m), 2.70 (3H, s), 3.78 (3H, s), 3.92 (2H, t),
25 4.36 (1H, m), 4.90 (1H, d). 6.82 (2H, d), 7.09 (2H,
d).


30

This Sheet Has Been Replaced



EXAMPLE 12

5



10

2-S-(Methylsulfonylamino)-3-[4-(6-aminohexyloxy)-
phenyl] propionic acid hydrochloride (2-5)

15 2-4 (0.1 g, 0.212 mmole) was treated with
LiOH (0.026 g, 1.06 mmole) as described for 1-8 to
provide 2-S-(methylsulfonylamino)-3-[4-(6-N-t-butyl-
oxycarbonylaminohexyloxy)phenyl]propionic acid
(0.125g) as a viscous oil.

20 ^1H NMR (300 MHz, CD_3OD) δ 1.30-1.55 (16H, m), 1.75
(2H, m), 2.63 (3H, s), 2.85 (1H, dd), 3.0-3.13 (3H,
m), 3.93 (2H, t), 4.17 (1H, m), 6.83 (2H, d), 7.20
(2H, d).

25 This acid was dissolved in EtOAc (20 mL) and
treated with HCl gas as described for 1-9. Solvent
removal provided a residue that was triturated with
30 mL Et_2O to provide pure 2-5 as a white solid (0.09
30 g).

This Sheet Has Been Replaced




^1H NMR (300MHz, CD_3OD), δ 1.40-1.60 (4H, m), 1.60 (2H, m), 1.69 (2H, m), 2.68 (3H, s), 2.82 (1H, dd), 2.92 (2H, t), 3.10 (1H, dd), 3.30 (2H, m), 3.97 (2H, t), 4.18 (1H, m), 6.83 (2H, d), 7.19 (2H, d).

Analysis for $\text{C}_{16}\text{H}_{26}\text{N}_2\text{O}_5\text{S} \cdot \text{HCl} \cdot 0.25 \text{ H}_2\text{O}$

Calculated: C = 48.11, H = 6.94, N = 7.01

Found: C = 48.16, H = 6.82, N = 6.98.

EXAMPLE 13




Methyl 2-S-(Butylsulfonylamino)-3-[4-(6-N-t-butyloxy-carbonylaminohexyloxy)phenyl]propionate (2-6)

2-3 (0.40 g, 1.01 mmole) was treated with butylsulfonyl chloride (0.47 g, 3.03 mmole) and NaHCO_3 (0.50 g, 6.0 mmole) as described for 1-8. Crude reaction product was purified by flash chromatography on silica gel eluting with 30% EtOAc/hexanes to give pure 2-6 (0.22 g) as a clear oil.

^1H NMR (300MHz, CDCl_3) δ 0.87 (3H, t), 1.35-1.54 (18 H, m), 1.61 (2H, m), 1.77 (2H, m), 2.74 (2H, t), 2.95 (1H, dd), 3.05-3.18 (3H, M), 3.90 (2H, t), 4.32 (1H, m), 4.72 (1H, m), 6.82 (2H, d), 7.07 (2H, d).



EXAMPLE 14



2-S-(Butylsulfonylamino)-3-[4-(6-aminohexyloxy)-
phenyl]propionic acid hydrochloride (2-7)

2-6 (0.2 g, 0.39 mmole) was treated
15 in THF (1)/H₂O (1)/CH₃OH(1) solution with LiOH
(0.05g, 2.12 mmole) as described for 1-8 to provide
2-S-(butylsulfonylamino)-3-[4-(6-N-t-butyloxycarbonyl-
aminohexyloxy)phenyl]propionic acid (0.235 g) as a
viscous oil.

20 ¹H NMR (300 MHz, CD₃OD) δ 0.83 (3H, t), 1.35-1.56
(16H, m) 1.76 (2H, m), 2.61 (2H, t), 2.79 (1H, ddd),
3.00-3.14 (3H, m), 3.92 (2H, t), 4.11 (1H, m), 6.82
(2H, d), 7.18 (2H, d).

25 This acid (0.235 g, 0.7 mmole) was dissolved
in EtOAc (30 mL) and treated with HCl gas as
described for 1-9. The residue was triturated with a
solution of ether (40 mL)/EtOAc (10mL) to provide 2-7
30 (0.17g) as a white solid.



^1H NMR (300MHz, CD_3OD) δ 0.85 (3H, t), 1.24 (2H, m),
1.35-1.60 (6H, m), 1.70 (2H, m), 1.80 (2H, m), 2.66
(2H, t), 2.78 (1H, dd), 2.92 (2H, t), 3.10 (1H, dd),
5 3.30 (1H, m), 6.85 (2H, d), 7.20 (2H, d).

Analysis for $\text{C}_{19}\text{H}_{32}\text{N}_2\text{O}_5\text{S}\cdot\text{HCl}$

Calculated: C = 52.22, H = 7.61, N = 6.41


Found: C = 51.80, H = 7.61, N = 6.33.

10

EXAMPLE 14A

2-S-(Butylsulfonylamino)-3-[4-(6-acetamidinohexyloxy)phenyl]propionic acid (2-7a)

15




A solution of 2-7 (1.0 g, 2.29 mmole) in THF
30 (30 ml) is treated with ethyl acetimidate (0.2 g,
2.29 mmol) and the resulting reaction mixture is
stirred at room temperature for 16 hours. The
solvent is then removed and the residue is
recrystallized from ethyl acetate to give pure 2-7a.




EXAMPLE 14B

5



10



15

2-S-(Butylsulfonylamino)-3-[4-(6-benzamidinohexyloxy)-phenyl]propionic acid (2-7b)

A solution of 2-7 (1.0 g, 2.29 mmole) in THF
20 (30 ml) is treated with ethyl benzimidate (0.34 g, 2.29 mmole) and the resulting solution is stirred at room temperature for 20 hrs. The solvent is removed and the residue is taken up in EtOAc, filtered and recrystallized to give pure 2-7b.

25

30


This Sheet Has Been Replaced



EXAMPLE 14C

5

10



15

2-S-(Butylsulfonylamino)-3-[4-(6-guanidinohexyloxy-
phenyl]propionic acid (2-7c)

20


A mixture of 2-7 (1.0 g, 2.29 mmol) and N-nitrosomethylthioguanidine (0.32 g, 2.29 mmol) is heated at 40° for 5 minutes in absolute EtOH (15 ml) and then is allowed to stand for 1 day at room temperature. The solvent is removed in vacuo and the residue is purified by flash chromatography on silica eluting with $\text{CHCl}_3(95)-\text{CH}_3\text{OH}(5)-\text{HOAc}(2)$ to give the desired nitroguanidino intermediate.

This is dissolved in 10% $\text{HCl}-\text{CH}_3\text{OH}$ (20 ml) and shaken in a Parr apparatus (50 psi) in the presence of 10% Pd-C (100 mg) at room temperature for 8 hours. The catalyst is then removed by filtration, the solvent is removed in vacuo, and the residue



dissolved in 10% aqueous HCl solution and heated at reflux for 2 hours. The solvent is removed in vacuo and the residue purified by chromatography on a Dowex 5 1-X2 column eluting with water to give pure 2-7c.

EXAMPLE 15



15

Methyl 2-S-(Benzyloxycarbonylamino)-3-[4-(6-N-t-butyl-oxycarboxylaminohexyloxy)phenyl]propionate (2-8)

2-3 (0.29 g, 0.735 mmole) was treated with
benzyloxycarbonyl chloride (0.14 g, 0.735 mmole) and
20 NaHCO₃ (0.185 g, 2.2 mmole) as described for 1-8.
The crude reaction product was purified by flash
chromatography on silica gel eluting with 1:1
hexanes/EtOAc to give pure 2-8 (0.27 g) as a clear
oil.


25

¹H NMR (300 MHz, CDCl₃) δ 1.47-1.69 (15H, m), 1.90
(2H, m), 2.18 (2H, s), 3.08 (2H, d), 3.25 (2H, m),
3.85 (3H, s), 4.05 (2H, t), 4.19-4.20 (4H, m), 4.80
30 (1H, d), 6.83 (2H, d), 7.12 (2H, d), 7.47 (5H, m).

This Sheet Has Been Replaced



EXAMPLE 16



10

2-S-(Benzyloxycarbonylamino)-3-[4-(6-aminohexyloxy)-phenyl]propionic acid hydrochloride (2-9)

15 2-8 (0.48 g, 0.875 mmole) was treated with LiOH (0.105 g, 4.37 mmole) as described for 1-8 to give 2-S-(benzyloxycarbonylamino)-3-[4-(6-N-t-butyloxy-carboxylaminohexyloxy)phenyl]propionic acid (0.4 g) as a foam.

20 ^1H NMR (300 MHz, CD_3OD) δ 1.30-1.52 (15H, m), 1.72 (2H, m), 2.81 (1H, dd), 3.00 (3H, m), 3.93 (2H, m), 4.06 (2H, m), 6.81 (2H, d), 7.13 (2H, d), 7.20-7.32 (5H, m).


25 This acid (0.4g, 0.75 mmole) was dissolved in EtOAc (30 mL) and treated with HCl gas as described for 1-9. Crude reaction product was triturated with ether to give pure 2-9 (0.35 g) as a

30 white solid.

This Sheet Has Been Replaced



^1H NMR (300 MHz, CD_3OD) δ 1.38–1.57 (4H, m), 1.65 (2H, m), 1.73 (2H, m), 2.71 (1H, dd), 2.89 (2H, t), 3.02 (1H, dd), 3.30 (3H, m), 3.94–4.15 (5H, m), 6.83 (2H, d), 7.15 (2H, d), 7.29 (5H, m).

EXAMPLE 16 A

2-S-(Benzylsulfonylamino)-3-[4-(6-(acetamidinohexyloxy-phenyl)]propionic acid (2-9a)

A solution of 2-9 (1.0 g, 2.1 mmol) in THF (30 ml) is treated with ethyl acetimidate (0.18 g, 2.1 mmol) as described in Example 14A to give pure 2-9a after recrystallization from ethyl acetate.

This Sheet Has Been Replaced




EXAMPLE 16 B

5

10

15



20

2-S-(Benzylsulfonylamino)-3-[4-(6-(guanidinohexyloxy))-phenyl]propionic acid (2-9b)

A mixture of 2-9 (1.0 g, 2.1 mmol) and N-nitrosomethylthioguanidine (0.29 g, 2.1 mmol) is treated as described for Example 14C to give pure 2-9b.

25


30

This Sheet Has Been Replaced




SCHEME 3


5




10



15



20



25

30

This Sheet Has Been Replaced



Methyl 2-S-amino-3-[4-(4-hydroxyphenyl)oxyphenyl]-
propionate (3-2).

CH₃OH (100 ml) was cooled to 0° and treated
5 with SOCl₂ (47 mmol) with stirring for 15 minutes at
0° and then 3-1 (1.5 g, 5.49 mmol) was added with
stirring for 16 hours as the temperature rose to
ambient.

The reaction mixture was filtered and the
10 solvent was removed to give an oil that provided 3-2
(1.57 g) after ether washing.

¹H NMR (300 MHz, CD₃OD) δ 3.10-3.30 (2H, m), 3.81
(3H, s), 6.76-6.90 (6H, m), 7.20 (2H, d).

15 Methyl 2-S-(N-Benzyloxycarbonylamino)-3-[4-(4-hydroxy-
phenyl)oxyphenyl]propionate (3-3).

A water(1)-dioxane(1) solution (10 ml) of
3-2 (0.2 g, 0.62 mmol) was cooled to 0°C and treated
with Na₂CO₃ (0.131 g, 1.23 mmole) and benzylchloro-
20 formate (0.619 mmol). After 1.5 hours of vigorous
stirring, the dioxane was removed at low pressure and
the residue diluted with H₂O and extracted with
EtOAc. The organic extract was washed with brine,
dried (Na₂SO₄) and the solvent removed to provide 3-3
25 as an oil.

¹H NMR (300 MHz, CDCl₃) δ 3.06 (2H, m), 3.75 (3H, s),
4.64 (1H, m), 5.10 (2H, m), 5.36 (1H, m), 6.83 (6H,
m), 7.00 (2H, d), 7.37 (5H, bs).

30 Methyl-2-S-(N-Benzyloxycarbonylamino)-3-[4-(4-N-t-
butyloxycarbonylpiperidin-4-yl)oxyphenyloxy]phenyl-
propionate (3-4).

A benzene (40 ml) solution of 3-3 (0.5 g,
1.18 mmol) was treated with N-t-butyloxycarbonyl-



piperidin-4-ol (0.24 g, 1.18 mmol) and Ph_3P (0.310 g, 1.18 mmol) while stirring at room temperature with constant N_2 purging. Diethyl azodicarboxylate (1.18 mmol) was added and the resulting solution was stirred at room temperature for 16 hours.

The solvent was then removed and the residue was purified by flash chromatography on silica gel eluting with hexane(70)-EtOAc(30) to provide pure 3-4.
 ^1H NMR (300 MHz, CDCl_3) δ 1.48 (9H, s), 1.80 (2H, m), 1.95 (2H, m), 3.08 (2H, m), 3.36 (2H, m), 3.76 (3H, s), 4.40 (1H, m), 4.63 (1H, m), 5.10 (1H, m), 5.25 (1H, m), 6.80-7.04 (8H, m), 7.36 (5H, bs).

15 Methyl 2-S-(Butylsulfonylamino)-3-[4-(4-N-t-butyl-oxycarbonylpiperidin-4-yl)oxyphenyloxy]phenyl-propionate (3-5).

A solution of 3-4 (0.5 g, 0.082 mmol) in EtOH (40 ml) was treated with 10% Pd/C (125 mg) and this suspension hydrogenated in a Parr flask at 50 psi for 1.5 hour. The catalyst was filtered off and the solvent removed to give the desired amino ester as a clear oil.

^1H NMR (300 MHz, CDCl_3) δ 1.48 (9H, s), 1.50-1.80 (8H, m), 1.91 (2H, m), 2.82 (1H, m), 3.04 (1H, m), 3.34 (2H, m), 3.76 (3H, s), 4.20 (1H, m), 7.90 (8H, m), 8.11 (2H, d).

This amino ester (0.36 g, 0.77 mmol) was dissolved in EtOAc (10 ml) and treated with NaHCO_3 (0.386 g, 4.6 mmol) and n-butylsulfonylchloride (1.53 mmol) with heating at reflux for 48 hours. The solvent was removed and the residue purified by flash chromatography on silica gel eluting with hexane(65)-EtOAc(35) to provide pure 3-5 as an oil.



¹H NMR (300 MHz, CDCl₃) δ 0.88-1.02 (4H, m), 1.25-1.45 (3H, m), 1.50 (9H, s), 1.51-1.80 (2H, m), 1.93 (2H, m), 2.80 (2H, m), 2.95-3.20 (2H, m), 3.21-3.40 (2H, m), 3.72 (2H, m), 3.74 (3H, s), 4.38 (2H, m), 4.80 (1H, d), 6.90 (6H, m), 7.10-7.27 (2H, m).

2-S-(Butylsulfonylamino)-3-[4-(piperidin-4-yl)oxy-phenyloxy]phenylpropionic acid hydrochloride (3-6).


10 A solution of 3-5 (0.2 g, 0.34 mmol) in THF(1)-H₂O(1)-CH₃OH(1) was treated with LiOH (0.075 g, 1.78 mmol) at room temperature for 8 hours. The solvent was removed and the residue was acidified with 10% KHSO₄ solution and this extracted several times
15 with EtOAc. The organic extracts were combined, washed with brine, dried (NaSO₄) and the solvent removed to give the desired acid. R_f = 0.3 [silica gel, 97(CHCl₃)-3(CH₃OH)-1(HOAc)].

¹H NMR (300 MHz, CDCl₃) δ 0.85 (3H, t), 1.20-1.30 (3H, m), 1.46 (9H, s), 1.50-2.0 (6H, m), 2.75 (2H, m), 2.97 (1H, m), 3.18 (1H, m), 3.33 (2H, m), 3.76 (2H, m), 4.35 (2H, m), 5.07 (1H, m), 6.89 (6H, m), 7.13 (2H, m).

25 This acid (0.15 g, 0.26 mmol) was dissolved in EtOAc and treated with HCl gas as described for 1-9 to give pure 3-6 as a white solid.

¹H NMR (300 MHz, CD₃OD) δ 0.89 (3H, t), 1.32 (2H, m), 1.53 (2H, m), 1.97-2.21 (4H, m), 2.75 (2H, m), 2.63 (1H, m), 3.20 (3H, m), 3.40 (2H, m), 4.14 (1H, m), 6.82-7.05 (6H, m), 7.23 (2H, m).



SCHEME 4

This Sheet Has Been Replaced



4[4-(N-Benzyloxycarbonylpiperidin-4-yl)-2-methyl]-
pentan-2-ol(4-2).

Methyl 4-(N-Benzyloxycarbonylpiperidin-4-yl)-
5 butanoate (4-1) (10.07 g, 0.032 mol) in THF (200 ml)
was cooled to 0°C and treated with CH₃MgI (0.095 mol)
for 3.0 hours. The reaction mixture was poured into
ice, acidified with 10% KHSO₄ and extracted with 3
portions of EtOAc. The combined organic extract was
10 washed with brine, dried (MgSO₄) and the solvent
removed. The residue was purified by flash
chromatography on silica gel eluting with
hexane(7)-EtOAc(3) to give pure 4-2. R_f = 0.3
(silica gel, hexane (7)-EtOAc(3)).

15 Methyl 2-S-(Butylsulfonylamino)-3-[4-(N-Benzyloxy-
carbonylpiperidin-4-yl)-2,2-dimethyl]butyloxyphenyl-
propionate (4-3).

N-n-Butylsulfonyl-L-tyrosine methyl ester
20 (7.21 g, 0.023 mole) was dissolved in a mixture of
4-2(1.0g), CH₂Cl₂ (30 ml) and benzene (250 ml).
Triphenylphosphine (5.97 g, 0.023 mole) was added and
after purging with N₂, diethyl azodicarboxylate (3.6
ml, 0.023 mole) was added at room temperature as the
25 reaction mixture turned red-orange in color.
Reaction mixture stirred at room temperature for 7
days. Solvent was removed and the residue was
purified by flash chromatography on silica gel
eluting with hexane(60)-EtOAc(40) to give pure 4-3.

30 ¹H NMR (300 MHz, CDCl₃) δ 0.88 (6H, t), 1.10-1.40
(12H, m), 1.43-1.78 (8H, m), 2.70-2.82 (4H, m),
2.95-3.10 (3H, m), 3.75 (3H, s), 4.18 (2H, m), 4.32



(1H, m), 5.13 (2H, s), 6.88 (2H, d), 7.06 (2H, d), 7.38 (5H, m).

- 5 2-S-(Butylsulfonylamino)-3-[4-(N-Benzyloxycarbonyl-piperidin-4-yl)-2,2-dimethyl]butyloxyphenylpropionic acid (4-4).

Dissolved 4-3 (0.64 g, 0.001 mole) in THF/H₂O/CH₃OH mixture and treated with LiOH (0.26 g, 0.0062 mole) at room temperature for 8 hours. Solvent removal, acidification (KHSO₄ solution) and EtOAc extraction provided crude 4-4 which was purified by flash chromatography on silica gel eluting with CHCl₃(97)-CH₃OH(3)-HOAc(1) to give pure 4-4.

¹H NMR (300 MHz, CDCl₃) δ 0.86 (6H, s), 1.05-1.50 (13H, m), 1.55-1.80 (5H, m), 2.77 (4H, m), 3.04 (2H, m), 4.10 (2H, bd), 4.17 (1H, m), 4.85 (1H, d), 5.14 (2H, s), 6.88 (2H, d), 7.13 (2H, d), 7.39 (5H, m).

- 20 2-S-(Butylsulfonylamino)-3-[4-(piperidin-4-yl)-2,2-dimethyl]butyloxyphenylpropionic acid (4-5).

To ammonium formate (0.23 g, 3.65 mmol) in CH₃OH (5 ml) was added 4-4 (0.22 g, 3.65 mmole) in 10 ml CH₃OH and then 10% Pd/C (100 mg) was added at room temperature. After 15 minutes the reaction mixture was passed thru a Solka Floc pad and the solvent removed. This residue was purified by flash chromatography on silica gel eluting with EtOH(9)-H₂O(1)-NH₄OH(1) to give pure 4-5.

¹H NMR (300 MHz, CD₃OD) δ 0.88 (6H, s), 1.15-1.40 (12H, m), 1.42-1.70 (7H, m) 1.90 (2H, d), 2.78-3.00 (6H, m), 3.06 (1H, dd), 3.35 (3H, m), 3.93 (1H, m), 6.86 (2H, d), 7.20 (2H, d).



SCHEME 5

5


10

15

20

25


30



This Sheet Has Been Replaced



5



5-1

10 Methyl 3-S-(Benzyloxycarbonylamino)-4-[4-(N-t-butyl-oxycarbonylpiperidin-4-yl)butyloxyphenyl]butyrate
(5-1).


15 A solution of compound 1-2 (1.0 g, 1.8 mmole) and N-methylmorpholine (0.21 mL, 1.9 mmole) in EtOAc (10 mL) was stirred at -15°C and treated with isobutyl chloroformate (0.24 mL, 1.8 mmole). After 15 minutes the heterogeneous mixture was treated portion-wise with an ethereal solution of diazomethane (0.5M:10 mL, 5.0 mmole), followed by continued stirring at 0° for 1.0 hour. The reaction mixture was then purged with argon for 10 minutes to
20 remove excess diazomethane. The organic phase was washed with 2 x 5 mL portions of H₂O, brine, dried (MgSO₄), and evaporated. The residue was then dissolved in CH₃OH (15 mL) and treated sequentially with triethylamine (0.7 mL, 5.0 mmole) and AgO₂CPh
25 (110 mg, 0.5 mmole) while stirring at ambient temperature to effect vigorous gas evolution.

30

This Sheet Has Been Replaced

After 30 minutes the solvent was evaporated and then the crude reaction product purified by flash chromatography on silica gel eluting with 4:1
5 hexane/EtOAc to give 5-1 (0.52 g) as an oil.
TLC R_f = 0.23 (30% EtOAc/hexane)

10



5-2

15 Methyl 3-S-Amino-4-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]butyrate (5-2).

To 5-1 (0.52 g, 0.9 mmole) dissolved in absolute ethanol (20 mL) was added 10% Pd/C (0.25 g) and the resulting suspension was hydrogenated under balloon pressure for 12 hours. The catalyst was then
20 filtered off and the solvent was removed in vacuo to give 5-2 (0.35 g) as an oil.

TLC R_f = 0.15 (9:1:1 $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{AcOH}$).


25

30

This Sheet Has Been Replaced



5



5-3

10 Methyl 3-S-(Butylsulfonylamino)-4-[4-N-t-butyloxy-carbonylpiperidin-4-yl]butyloxyphenyl]butyrate (5-3).

To 5-2 (0.36 g, 0.8 mmole), triethylamine (170 μ L, 1.2 mmole), 4-dimethylaminopyridine (12 mg, 0.1 mmole), and THF (5 mL) at 0°C was added n-butylsulfonyl chloride (130 μ L, 1.0 mmole) with stirring. The cooling bath was removed and stirring was continued for 6 hours. The reaction mixture was diluted with 10 mL of EtOAc and then washed with 2x5 mL H₂O, brine, dried (MgSO₄), and concentrated. The crude reaction product was purified by flash chromatography on silica gel eluting with 4:1 hexane/EtOAc to give 5-3 (180 mg) as an oil.


25 ¹H NMR (300 MHz, CDCl₃) δ 1.12 (2H, m), 1.25-1.83 (13H, m), 1.29 (3H, t), 1.47 (9H, s), 2.68 (6H, m), 2.87 (2H, d), 3.73 (3H, s), 3.93 (2H, t), 4.08 (1H, m), 4.72 (1H, d), 6.87 (2H, d), 7.12 (2H, d).

30

This Sheet Has Been Replaced



5



5-4

3-S-(Butylsulfonylamino)-4-[4-N-t-butyloxycarbonyl-
10 piperidin-4-yl]butyloxyphenyl]butanoic acid (5-4).

Compound 5-3 (175 mg, 0.33 mmole) in CH₃OH
(4.0 mL) was treated with 1N NaOH (1.0 mL, 1.0 mmole)
followed by continued stirring at ambient temperature
for 20 hours. The reaction mixture was diluted with
15 15 mL EtOAc and then washed with 10 mL 5% KHSO₄ and
brine, dried (MgSO₄), and concentrated to give 5-4
(160 mg) as an oil.

TLC R_f = 0.31 (9:0.5:0.5 CH₂Cl₂/CH₃OH/AcOH).

20


25

This Sheet Has Been Replaced



30

5



5-5

10 3-S-(Butylsulfonylamino)-4-[4-piperidin-4-yl]butyloxy-phenylbutanoic acid (5-5)

15 To a stirred solution, of compound 5-4 (160 mg, 0.30 mmole), CH_2Cl_2 (2.0 mL), and anisole (100 μL) at 0°C was added $\text{CF}_3\text{CO}_2\text{H}$ (1.0 mL). After 1.5 hours at 0°C the solvents were evaporated and the crude reaction product purified by flash chromatography on silica gel eluting with 10:0.8:0.8 ethanol/ H_2O /conc. NH_4OH to give 5-5 (42 mg) as a solid.


20 ^1H NMR (300 MHz, $\text{D}_2\text{O}/\text{CF}_3\text{CO}_2\text{D}$) δ 0.82 (3H, t), 1.10-1.70 (11H, m), 1.80 (m, 2H), 1.98 (m, 2H), 2.48 (2H, t), 2.72 (3H, m), 3.00 (3H, m), 3.43 (2H, m), 3.96 (1H, m), 4.10 (2H, t), 7.01 (2H, d), 7.32 (2H, d).

25

This Sheet Has Been Replaced

30



SCHEME 6

This Sheet Has Been Replaced



Methyl 2-S-(N-Benzyloxycarbonylamino)-3-[4-(3-chloro-propyloxyphenyl)propionate (6-1).

5 Treatment of a DMF solution of 1-1 (0.95 g, 2.9 mmol) and 3-chloro-1-tosyloxypropane (0.84 g, 3.19 mmol) with cesium carbonate (0.47 g, 1.45 mmole) gave a solution that was stirred at room temperature overnight. The reaction mixture was then diluted with H₂O and extracted with ether. The ether extract
10 was washed with brine, dried (Na₂SO₄) and the solvent removed to give an oily residue. This was purified by flash chromatography on silica gel eluting with EtOAc(5)-hexane(95) to afford 6-1 as a clear oil. R_f 0.5 (silica gel eluting with EtOAc(30)-hexane(70)).

15

Methyl 2-S-(Benzyloxycarbonylamino)-3-[4-(3-iodo-propyloxyphenyl)propionate (6-2).

A solution of 6-1 (0.6 g, 1.5 mmol) in acetone was treated with sodium iodide (1.1 g, 7.5
20 mmol) and the resulting solution was heated at reflux for 16 hours. The reaction mixture was then diluted with ether, washed with water, brine and dried (Na₂SO₄). Solvent removal gave an oil that was purified by flash chromatography on silica gel
25 eluting with hexane(90)-EtOAc(10) to give 6-2 as a clear oil.

¹H NMR (300 MHz, CDCl₃) δ 1.85-2.08 (4H, m), 3.04 (2H, m), 3.26 (2H, t), 3.71 (3H, s), 3.95 (2H, t),
30 4.60 (1H, m), 5.00-5.21 (3H, m), 6.78 (2H, d), 6.99 (2H, d), 7.33 (5H, m).

This Sheet Has Been Replaced



Methyl 2-S-(N-Benzyloxycarbonylamino)-3-[4-(2,6-dimethylpiperazin-4-yl)propyloxyphenyl]propionate (6-3).

5 A solution of 6-2 (0.1 g, 0.2 mmol) and 2,6-dimethylpiperazine (0.068 g, 0.6 mmol) in 1 ml THF was stirred at room temperature for 20 hours. The solvents were removed at low pressure to provide 6-3 as a clear oil.

10 ^1H NMR (300 MHz, CDCl_3) δ 1.45 (4H, d), 1.82 (3H, m), 2.65 (2H, m), 2.79 (2H, m), 3.05 (1H, m), 3.18 (2H, bd), 3.60 (1H, m), 3.72 (3H, s), 3.96 (2H, m), 4.62 (1H, m), 5.10 (2H, s), 5.21 (1H, m), 6.79 (2H, d), 7.00 (2H, d), 7.35 (5H, bs).


15 2-(N-Benzyloxycarbonylamino)-3-[4-(2,6-dimethylpiperazin-4-yl)propyloxyphenyl]propionic acid (6-4).

6-3 (0.090 g, 0.2 mmol) in methanol was treated with 1N NaOH (0.7 ml) at room temperature for 20 16 hours. The solvent was removed to give crude acid which was purified by flash chromatography on silica gel eluting with isopropanol(10)- NH_4OH (1)- H_2O (1) to provide pure 6-4, R_f 0.25.

25 ^1H NMR (300 MHz, CD_3OD) δ 1.65-1.85 (4H, m), 2.60-2.70 (2H, m), 2.80-2.95 (6H, m), 3.11 (8H, m), 3.52 (2H, m), 3.65-3.75 (2H, m), 3.82 (2H, t), 4.17 (1H, m), 4.70 (2H, s), 4.85 (2H, m), 6.63 (2H, d), 6.92 (2H, d), 7.10 (5H, bs).

30



SCHEME 7

This Sheet Has Been Replaced



Methyl 2-S-(N-Benzyloxycarbonylamino)-3-[4-(N-t-butyl-oxycarbonylpiperidin-4-yl)propyloxyphenyl]propionate (7-1).

5 A solution of 1-1 (4.0 g, 2.6 mmol) and
3-(N-Boc-piperidin-4-yl)propyl iodide (1.1 g, 3.3
mmol) in 40 ml DMF was treated with cesium carbonate
(0.4 g, 1.35 mmol) and the resulting solution was
stirred at room temperature for 20 hours. The
10 solvent was removed and the residue was taken up in
EtOAc, washed with water, brine and dried (Na_2SO_4).
Solvent removal provided a residue that was purified
by flash chromatography on silica gel eluting with
4:1 hexane(80)-EtOAc(20) to give pure 7-1 as a clear
15 oil.

^1H NMR (300 MHz, CDCl_3) δ 1.10 (2H, m), 1.37-1.45
(11H, m), 1.65-1.82 (4H, m), 2.68 (2H, m), 3.03 (2H,
m), 3.71 (3H, s), 3.90 (2H, t), 4.08 (2H, bd), 4.61
20 (1H, m), 5.10 (1H, s), 5.18 (1H, m), 6.79 (2H, d),
7.00 (2H, d), 7.35 (5H, bs).

2-(S)-(N-Benzyloxycarbonylamino)-3-[4-(N-t-butyloxy-
carbonylpiperidin-4-yl)propyloxyphenyl]propionic acid
25 (7-2).

7-1 (0.5 g, 0.9 mmol) in methanol (12 ml)
was treated with 1N NaOH (3 ml) at room temperature
for 16 hours. The solvent was then removed and the
residue acidified with 5% KHSO_4 solution. This was
30 extracted with EtOAc several times and the combined
organic extracts were washed with brine and dried
(Na_2SO_4). Solvent removal gave 7-2 as a clear oil.

This Sheet Has Been Replaced



¹H NMR (300 MHz, CDCl₃) δ 1.10 (2H, m), 1.37-1.52 (12H, m), 1.62-1.85 (5H, m), 2.66 (2H, t), 3.10 (2H, m), 4.89 (2H, t), 4.10 (4H, m), 4.62 (1H, m), 5.09 (1H, s), 5.19 (1H, m), 6.79 (2H, d) 7.03 (2H, d), 7.34 (5H, bs).

Methyl 3-S-(N-Benzoyloxycarbonylamino)-4-[4-(N-t-butyl-oxycarbonylpiperidin-4-yl)propyloxyphenyl]butanoate (7-3).

To a stirred solution of 7-2 (1.6 g, 2.9 mmol) in EtOAc at -15°C was added isobutyl-chloroformate (2.9 mmol) and N-methylmorpholine (2.9 mmol) and the resulting solution was stirred for 0.5 hours at -15°. Then, diazomethane (5.0 mmol in Et₂O) was added and the reaction mixture was stirred at 0° for 20 minutes. The reaction mixture was purged with argon, diluted with EtOAc and washed with water. The organic phase was dried (MgSO₄) and the solvent removed to provide the desired diazoketone.

¹H NMR (300 MHz, CDCl₃) δ 1.10 (2H, m), 1.35-1.50 (12H, m), 1.55-1.85 (6H, m), 2.68 (2H, bt), 2.95 (2H, d), 3.90 (2H, t), 4.09 (3H, m), 4.42 (1H, m), 5.06 (1H, m), 5.20 (1H, m), 5.35 (1H, m), 6.80 (2H, d), 7.06 (2H, d), 7.35 (5H, bs).

This diazoketone (1.63 g, 2.9 mmol) was dissolved in CH₃OH (20 ml) and treated at room temperature with a CH₃OH solution (5 ml) of silver benzoate (0.22 mg, 0.96 mmoles) and triethylamine (1.25 ml). After a few minutes the reaction became black with gas evolution apparent. After 0.5 hours the solvent was removed and the residue was purified



by flash chromatography on silica gel eluting with 4:1 hexane(80) EtOAc(20) to give 7-3 as an oil.

5 ^1H NMR (300 MHz, CDCl_3) δ 1.12 (2H, m), 1.37-1.47 (12H, m), 1.60 (2H, s), 1.65-1.83 (4H, m), 2.49 (2H, m), 2.62-2.91 (4H, m), 3.67 (3H, s), 3.90 (2H, t), 4.03-4.20 (4H, m), 5.08 (2H, s), 5.24 (1H, m), 6.79 (2H, d), 7.05 (2H, d), 7.32 (5H, bs).

10

3-S-(N-Benzyloxycarbonylamino)-4-[4-(piperidin-4-yl)-propyloxyphenyl]butanoic acid (7-4).

A solution of 7-3 (0.3 g, 0.53 mol) was treated with 1N NaOH (1.7 ml) and the resulting
15 mixture was stirred at room temperature for 16 hours. The solvent was removed and the residue acidified with 5% aq KHSO_4 solvent and this was extracted several times with EtOAc. The combined organics were washed with brine, dried (NaSO_4) and
20 the solvent removed to give the desired acid.

^1H NMR (300 MHz, CD_3OD) δ 1.10 (2H, m), 1.40-1.52 (12, m), 1.65-1.84 (6H, m), 2.54-2.93 (8H, m), 3.92 (2H, t), 4.05-4.12 (3H, m), 5.10 (2H, s), 6.71 (2H, d), 7.08 (2H, d), 7.35 (5H, m).

This acid was dissolved in CH_2Cl_2 (4 ml) and anisole (0.41 mmole) was added, followed at 0° with trifluoroacetic acid (2 ml). After 2.5 hours
30 stirring at 0° , the solvents were removed and the residue purified by flash chromatography on silica gel eluting with EtOH(10)- NH_4OH (1)- H_2O (1) to give pure 7-4 as a white solid.

This Sheet Has Been Replaced



¹H NMR (300 MHz, CD₃OD) δ 1.3-1.5 (4H, m), 1.6 (1H, m), 1.75-1.85 (2H, m), 1.95 (2H, d), 2.54 (2H, m), 2.72 (2H, m), 2.93 (2H, t), 3.32 (6H, m), 3.92 (2H, t), 4.11 (1H, m), 4.95 (2H, m), 6.75 (2H, d), 7.05 (2H, d), 7.25 (5H, m).

10

15

20

25

30

This Sheet Has Been Replaced

5

10


15

20

25

30


SCHEME 8



This Sheet Has Been Replaced



5



10

Methyl 2-S-(Hexanoylamino)-3-(4-iodophenyl)propionate
(8-2)

A suspension of 8-1 (1.01 g, 2.96 mmol) in
20 ml CHCl_3 was cooled to 0° and pyridine (1.43 ml,
17.7 mmol) was added followed by hexanoylchloride
(1.25 ml, 8.88 mmol). After 20 minutes all 8-1 was
consumed. Water (25 ml) was then added carefully and
this mixture was extracted with EtOAc (150 ml). The
separated organic phase was washed with 10% KHSO_4 ,
brine, dried (Na_2SO_4) and the solvent was removed to
give a white solid. This was purified by flash
chromatography on silica gel eluting with 5%
 $\text{Et}_2\text{O}/\text{CHCl}_3$ to give pure 8-2 (1.07 g) as a white solid.


25

^1H NMR (300 MHz, CDCl_3) δ 0.88 (3H, t), 1.27 (4H, m),
1.60 (2H, m), 2.09 (2H, t), 3.05 (2H, m), 3.75 (3H,
s), 4.88 (1H, m), 5.93 (1H, m), 6.83 (2H, d), 7.60
(2H, d).

30

This Sheet Has Been Replaced





5-(N-*t*-Butyloxycarbonylpiperidin-4-yl)-1-trimethyl-1-silylpent-3-ene-1-yne (8-4).

15 A suspension of 3-trimethylsilyl-2-propynyl)-triphenyl phosphonium bromide (3.0 g, 6.62 mmoles) (Aldrich) in 50 ml THF was cooled to -78° and treated with *n*-BuLi (6.62 mmoles) dropwise. The resulting solution was allowed to warm to -40° and was then stirred for 0.5 hours to give a deep red solution.


20 After cooling to -78°C the reaction mixture was treated with 8-3 (1.07 g, 4.73 mmoles) in 15 ml THF and was allowed to warm to 0° with stirring for 1 hour. The reaction was quenched with 50 ml H_2O and this was extracted with EtOAc (200 ml). The organic

25 phase was separated, dried (Na_2SO_4) and stripped to provide as residue that was purified by flash chromatography on silica gel eluting with 10% EtOAc/hexane to provide pure 8-4, (2.02 g), $R_f = 0.3$.

30 ^1H NMR (300 MHz, CDCl_3) δ 0.10 (9H, s), 0.70-1.10 (4H, m), 1.10-1.40 (13H, m), 1.40-1.60 (3H, m), 1.83 (3H, m), 2.40-2.60 (3H, m), 3.85 (3H, m), 5.35 (1H, t), 6.00 (1H, m).



5



10 5-(N-t-Butyloxycarbonylpiperidin-4-yl)pent-3-en-1-yne (8-5)

A solution of 8-4 (0.815 g, 2.54 mmoles) in 60 ml THF was treated with 12 ml H₂O and lithium hydroxide hydrate (0.96 g, 2.28 mmoles). The reaction mixture was stirred at room temperature for 6 hours during which time the color became dark orange. The reaction mixture was then diluted with Et₂O (75 ml) and the aqueous phase was separated and washed with 3x75 ml Et₂O. The combined organic extacts were washed with brine, dried and stripped. The resulting residue was purified by flash chromatography on silica gel eluting with 10% EtOAc/hexanes to give 0.63 g pure 8-5.


25 ¹H NMR (300 MHz, CDCl₃) δ 1.0-1.25 (3H, m), 1.25-1.60 (11H, m), 1.60-1.75 (3H, m), 2.06 (2H, t), 2.30 (1H, t), 2.60-2.78 (2H, m), 4.07 (2H, m), 5.51 (1H, m), 6.22 (1H, m).

30

This Sheet Has Been Replaced



5



10

Methyl 2-S-(Hexanoylamino)-3-[4-(5-N-t-butyloxy-carbonylpiperidin-4-yl)pent-3-ene-1-ynephenyl]-propionate (8-6).

15

A solution of 8-5 (0.3 g, 1.2 mmoles) and 8-2 (0.58 g, 1.4 mmoles) in diethylamine (6 ml) was purged with N_2 and bis-triphenylphosphine palladium chloride (0.049 g, 0.07 mmoles) was added followed by cuprous iodide (7 mg, 0.035 mmoles) and the suspension was purged again. After several minutes the reaction mixture became homogeneous and this solution was stirred for 16 hours at room temperature.

20

25


The solvent was removed at high vacuum and the residue was dissolved in pH 7 buffer and extracted with Et_2O . The organic extract was washed with 10% $KHSO_4$, brine, then dried (Na_2SO_4) and stripped. The residue was purified by flash chromatography on silica gel eluting with 20% $EtOAc$ /hexanes to give 0.28 g pure 8-6. $R_f = 0.3$ (20% $EtOAc$, hexanes).

30

1H NMR (300 MHz, $CDCl_3$) δ 0.90 (3H, m), 1.05-1.40 (9H, m), 1.52 (6H, s), 1.58-1.75 (4H, m), 2.07 (2H, m), 1.70 (2H, m), 3.14 (2H, m), 3.75 (2H, m), 4.10 (2H, m), 4.89 (1H, m), 5.70 (1H, m), 5.94 (1H, m), 6.18 (1H, m), 7.03 (2H, m), 7.38 (2H, m).



5



10

2-S-(Hexanoylamino)-3-[4-(5-Piperidin-4-yl)pentyl-phenyl]propionic acid (8-7)

15

20

8-6 (0.275 g, 0.52 mmoles) was dissolved in EtOH and 2 ml of H₂O was added along with 5 drops of HOAc. Pd-C (100 mg) was added and the resulting suspension was hydrogenated on a Paar shaker (50 psi) for 4 hours. The reaction mixture was filtered through Solka-Floc and the resulting solvent was removed. The resulting residue was purified by flash chromatography on silica gel eluting with 35% EtOAc/hexanes to give 0.22 g of methyl 2-S-hexanoyl amino-3-[4-5-N-t-butyloxycarbonylpiperidin-4-yl)-pentylphenyl propionate.

25

¹H NMR (300 MHz, CDCl₃) δ 0.85 (3H, t), 1.00-1.35 (12H, m), 1.45 (9H, s), 1.50-1.65 (6H, m), 2.15 (2H, t), 2.50-2.65 (4H, m), 3.05 (2H, m), 3.71 (3H, s), 4.04 (2H, m), 4.83 (1H, m), 5.96 (1H, m), 6.98 (2H, d), 7.04 (2H, d).

30

This ester (0.17 g, 0.32 mmoles) was suspended in 10 ml of 1:1 THF/H₂O and CH₃OH (2 ml), lithium hydroxide hydrate (0.067 g, 1.6 mmoles) was added and the reaction was stirred for 2.0 hours at room temperature. The solvent was then removed and the residue was taken up in H₂O. This was acidified



to pH 2-3 with 10% KHSO_4 , and extracted with EtOAc. The organic extract was washed with brine, dried (Na_2SO_4) and stripped to give 0.050g of the desired acid.

^1H NMR (300 MHz, CDCl_3) δ 0.85 (3H, m), 0.95-1.42 (15 H, m), 1.47 (9H, s), 1.50-1.70 (7H, m), 2.18 (2H, m), 2.48-2.72 (5H, m), 5.02-5.30 (2H, m), 4.03 (2H, m), 4.84 (1H, m), 6.05 (1H, m), 7.06 (4H, s).

This acid (0.15 g, 0.29 mmoles) was dissolved in EtOAc (25 ml), cooled to -70° and treated with HCl gas for 10 minutes. The temperature was allowed to rise to -20° over 0.5 hr. The reaction mixture was purged with N_2 and the solvent was removed. The residue purified by flash chromatography on silica gel eluting with 9:1:1 EtOH/ H_2O / NH_4OH to give pure 8-7, 0.040 g as a white solid.

^1H NMR (300 MHz, CD_3OD) δ 0.78 (3H, t), 1.05-1.30 (9H, m), 1.32-1.56 (4H, m), 1.74 (2H, d), 2.03 (2H, m), 2.42 (2H, m), 2.70-2.85 (3H, m), 3.04 (1H, dd), 3.21 (2H, m), 4.38 (1H, m), 6.92 (2H, d), 7.00 (2H, d).

In the above Schemes and Examples, various reagent symbols have the following meanings:

- BOC: t-butoxycarbonyl.
Pd-C: Palladium on activated carbon catalyst.
DMF: Dimethylformamide.
CBZ: Benzyloxycarbonyl.



BOP: Benzotriazol-1-yloxytris(dimethylamino)-
phosphonium hexafluorophosphate.

EtOAc: ethyl acetate

5 DMF: dimethylformamide

CH₂Cl₂: methylene chloride

CHCl₃: chloroform

MeOH: methanol

HOAc: acetic acid

10

Suitable alternative protecting groups
that can be used in the preparation of the present
invention include benzyl ester, cyclohexyl ester,
4-nitrobenzyl ester, t-butyl ester, 4-pyridylmethyl
15 ester, benzyloxycarbonyl, isonicotinyloxycarbonyl,
O-chlorobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl,
p-methoxybenzyloxycarbonyl, t-amylloxycarbonyl,
isobornyloxycarbonyl, adamantyloxycarbonyl,
2-(4-biphenyl)-2-propyloxy-
20 carbonyl and 9-fluorenylmethoxycarbonyl.

In addition to those compounds specifically
exemplified above, additional compounds of the
present invention are set forth in tabular form
below. These compounds are synthesized by use of the
25 synthetic routes and methods described in the above
Schemes and Examples and variations thereof well
known to those of ordinary skill in the art, and not
requiring undue experimentation. All variables

30


This Sheet Has Been Replaced



listed in the Tables below are with reference to the following generic structure:

5

10



15









20

25

30

This Sheet Has Been Replaced



Example	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶
18		-CH ₂ CO ₂ C ₆ H ₅	-H	-(CH ₂) ₃ OCH ₃		-H
19		-H	-(CH ₂) ₂ OCH ₃	-CH ₃		-C ₂ H ₅
20		-CF ₂ CF ₃	-H	-C ₂ H ₅		-H
21		-(CH ₂) ₂ NH C ₂ H ₅	-CH ₃	-C ₃ H ₇		-CH ₃
22		-C(=O)CH ₃	-H	-t-Bu	-CO ₂ H	-F
23		-H		-CH ₂ C ₆ H ₅	-CO ₂ CH ₃	-H

30

25

20


15

10

5

This Sheet Has Been Replaced



Example	R ⁷	X	Y	Z	m	n	p
18	-CH ₃	-C≡C-	C_6H_5 -CH-	-	1	1	1
19	-C ₆ H ₅	CH_3 -C=C- CH ₂ CN	O -C-NH	-CH ₂	2	3	1
20	-H	CHOCH_3 -CH-	O -NHC-	OCH_3 -CH-	4	1	1
21	-OCH ₃	C_6H_5 -N-C- O	-CH ₂	OH -CH-	6	2	2
22	-H	O -C-NH C ₆ H ₅	-CH ₂	-O-	5	1	5
23	-CH ₃		CH_3 -CH-	-S-	5	2	2



This Sheet Has Been Replaced



	5	10	15	20	25	30
	R ⁵	R ⁴	R ³	R ²	R ¹	Example
	-CO ₂ C ₄ H ₉	-(CH ₂) ₂ C ₆ H ₅	-H	-S-CC ₂ H ₅		24
	-H	-S-COC ₂ H ₅		-S-CC ₂ H ₅		25
	-C ₂ H ₅	-COCH ₂ C ₆ H ₅	-CH ₂ SO ₂ CH ₃	-CF ₃	H ₂ NC-NH-	26
	-CH ₂ CO ₂ C ₂ H ₅		-(CH ₂) ₃ SCH ₃	-(CH ₂) ₂ NHC(=O)CH ₃		27
	-F		-(CH ₂) ₃ SCH ₃	-(CH ₂) ₂ NH-CH ₂ C ₆ H ₅		28
	-H		-CH ₂ -	-(CH ₂) ₂ CH ₂ OH	CH ₃ NHC-NH-	29
	-Cl		-(CH ₂) ₂ -			30
	-CH ₂ C ₆ H ₅	-CO ₂ H	-CH ₂ C(=O)-	-H		31

This Sheet Has Been Replaced



30	25	20	15	10	5		
Example	R ⁷	X	Y	Z	m	n	p
24	-H	-O-	$\begin{array}{c} \text{C}_4\text{H}_9 \\ \\ \text{-CH-} \end{array}$	-SO-	2	4	3
25	-OCH ₃	$\begin{array}{c} \text{O} \\ \\ \text{-C-} \end{array}$	$\begin{array}{c} \text{CH}_2\text{C}_6\text{H}_5 \\ \\ \text{-CH-} \end{array}$	-SO ₂ -	1	3	1
26	-CN	$\begin{array}{c} \text{S} \\ \\ \text{-C-} \end{array}$	$\begin{array}{c} \text{CO}_2\text{C}_2\text{H}_5 \\ \\ \text{-CH-} \end{array}$	-NH-	2	2	2
27	-H		-O-	$\begin{array}{c} \text{CH}_3 \\ \\ \text{-N-} \end{array}$	3	3	3
28	-CH ₃	-CH ₂ -	$\begin{array}{c} \text{CH}_2\text{C}_6\text{H}_5 \\ \\ \text{-N-} \end{array}$	$\begin{array}{c} \text{C}_6\text{H}_5 \\ \\ \text{-N-} \end{array}$	4	1	1
29	-H	-S-	$\begin{array}{c} \text{CH}_3 \\ \\ \text{-CH-} \end{array}$	$\begin{array}{c} \text{CH}_2\text{C}_6\text{H}_5 \\ \\ \text{-N-} \end{array}$	0	5	5
30	-(CH ₂) ₂ C ₆ H ₅		$\begin{array}{c} \text{C}_6\text{H}_5 \\ \\ \text{-CH-} \end{array}$	$\begin{array}{c} \text{C}_4\text{H}_9 \\ \\ \text{-N-} \end{array}$	3	2	1
31	-H	$\begin{array}{c} \text{CN} \\ \\ \text{-CH-} \end{array}$	-O-	-	1	2	4

This Sheet Has Been Replaced



Example	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶
32		-H	-(CH ₂) ₄ CN	-C ₆ H ₁₇		-C ₃ H ₇
33		-CH ₂ OC ₆ H ₅	-C ₃ H ₇		-CO ₂ CH ₃	-H
34		-t-Bu	-CH ₂ C ₆ H ₅		-CO ₂ H	-CH ₃
35			-H	-CH ₃	-CO ₂ H	-C ₂ H ₅
36		-H		-(CH ₂) ₃ NH ₂	-CO ₂ C ₄ H ₉	-OC ₃ H ₇
37		-H	-H		-CO ₂ H	-CH ₂ C ₄ H ₉
38		-CH ₂ C ₆ H ₅	-H	-(CH ₂) ₄ OCH ₃	-CO ₂ C ₂ H ₅	-CH ₃
39		-(CH ₂) ₃ OCH ₃	-C ₂ H ₅		-P(OH) ₂	-CH ₂ SO ₂ CH ₃

This Sheet Has Been Replaced



5


10

15

20

25

30

Example	R'	X	Y	Z	m	n	p
32	-H	-CH ₃	$\begin{array}{c} \text{CH}_3\text{CO}_2\text{CH}_3 \\ \\ \text{-CH-} \end{array}$	$\begin{array}{c} \text{O} \\ \\ \text{-C-} \end{array}$	6	4	6
33				$\begin{array}{c} \text{S} \\ \\ \text{-C-} \end{array}$	8	2	8
34	-Br	$\begin{array}{c} \text{-C-} \\ \\ \text{S} \end{array}$		-C=C-	3	1	3
35	-H	-CH ₃	-N(CH ₃)-	$\begin{array}{c} \text{O} \\ \\ \text{-C-} \end{array}$	1	1	1
36	-H	$\begin{array}{c} \text{-C-} \\ \\ \text{S} \end{array}$	$\begin{array}{c} \text{CH}_2\text{CH}_3 \\ \\ \text{-N-} \end{array}$	-C=C-	2	1	2
37	-H	$\begin{array}{c} \text{CH}_3 \\ \\ \text{-CH-} \end{array}$	-O-	$\begin{array}{c} \text{H}_3\text{C} \quad \text{CH}_3 \\ \quad \\ \text{-C=C-} \end{array}$	1	2	1
38	-OCH ₃	$\begin{array}{c} \text{CH}_3 \\ \\ \text{-C-} \end{array}$ C ₂ H ₅	-NCH ₃	$\begin{array}{c} \text{C}_2\text{H}_5 \\ \\ \text{-C=CH-} \end{array}$	0	0	5
39	-H	-O-	$\begin{array}{c} \text{CH}_3 \\ \\ \text{-CH-} \end{array}$	-	6	0	6

This Sheet Has Been Replaced



5	R ⁴		R ³		R ²		R ¹	
10	R ⁴		R ³		R ²		R ¹	
15	R ⁴		R ³		R ²		R ¹	
20	R ⁴		R ³		R ²		R ¹	
25	R ⁴		R ³		R ²		R ¹	
30	R ⁴		R ³		R ²		R ¹	
35	R ⁴		R ³		R ²		R ¹	
40	R ⁴		R ³		R ²		R ¹	
41	R ⁴		R ³		R ²		R ¹	
42	R ⁴		R ³		R ²		R ¹	
43	R ⁴		R ³		R ²		R ¹	
44	R ⁴		R ³		R ²		R ¹	
45	R ⁴		R ³		R ²		R ¹	
46	R ⁴		R ³		R ²		R ¹	
47	R ⁴		R ³		R ²		R ¹	
48	R ⁴		R ³		R ²		R ¹	




This Sheet Has Been Replaced



30	25	20	15	10	5			
Example	R ⁷	X	Y	Z	m	n	p	
40	-CH ₃	-NH	-SO ₂	-O-	2	4	1	
41	-OH	-NCH ₂ C ₆ H ₅	-SO ₂	$\begin{array}{c} \text{O} \\ \parallel \\ \text{-C-} \end{array}$	3	1	0	
42	-H	$\begin{array}{c} \text{S} \\ \parallel \\ \text{-C-} \end{array}$	-CH ₂ -	$\begin{array}{c} \text{S} \\ \parallel \\ \text{-C-} \end{array}$	1	1	1	
43	-H	-CH ₂ -	$\begin{array}{c} \text{S} \\ \parallel \\ \text{-C-} \end{array}$	$\begin{array}{c} \text{O} \\ \parallel \\ \text{-NHC-} \end{array}$	3	4	1	
44	-CF ₂ CF ₃	-O-	-CH ₂ -	$\begin{array}{c} \text{O} \\ \parallel \\ \text{-NHC-} \end{array}$	2	0	10	
45	-H	$\begin{array}{c} \text{H}_3\text{C} \text{ F} \\ \quad \\ \text{-C=C-} \end{array}$	-SO ₂	$\begin{array}{c} \text{O} \text{ CH}_3 \\ \parallel \quad \\ \text{-C-N-} \end{array}$	1	3	1	
46	-OH	$\begin{array}{c} \text{O} \text{ CH}_3 \\ \parallel \quad \\ \text{-C-N-} \end{array}$	-CH ₂ -	-	10	2	2	
47	-H	-CH ₂ -	$\begin{array}{c} \text{OH} \\ \\ \text{-CH} \end{array}$	$\begin{array}{c} \text{S} \\ \parallel \\ \text{-C-} \end{array}$	0	2	4	
48	-CF ₃	-NH	-CH ₂ -	$\begin{array}{c} \text{O} \\ \parallel \\ \text{-C-} \end{array}$	3	1	2	

This Sheet Has Been Replaced



30	25	20	15	10	5	
Example	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶
49	$\text{CH}_3\text{NH}-\text{C}(\text{NHCH}_3)=$	$-\text{CH}_2\text{C}(=\text{O})\text{CH}_3$	-H		$-\text{CO}_2\text{C}_2\text{H}_5$	$-\text{CH}_2\text{NO}_2$
50	$\text{H}_2\text{NC}(\text{NH})=\text{NH}-$	$-\text{CH}_2\text{SC}_6\text{H}_5$	$-\text{CH}_3$	$-\text{C}_2\text{H}_5$	$-\text{CO}_2\text{C}_3\text{H}_7$	-H
51	$\text{C}_2\text{H}_5\text{O}_2\text{CCH}_2\text{CH}_2-\text{NH}-$	$-\text{CF}_3$	-H	$-\text{C}_4\text{H}_7$	$-\text{CO}_2\text{CH}_2\text{C}_6\text{H}_5$	
52		$-\text{CH}_3$	$-\text{H}_2\text{CC}(=\text{S})\text{C}_6\text{H}_5$	$-\text{C}_3\text{H}_7$	$-\text{CO}_2\text{C}(=\text{O})\text{CH}_3$	$-\text{OC}_4\text{H}_9$
53	$\text{H}_3\text{C}-\text{C}_6\text{H}_4(\text{N})-(\text{CH}_2)_2\text{HN}-$	$-\text{CH}_2\text{CN}$	-H	$-\text{C}_6\text{H}_{13}$	$-\text{CO}_2\text{C}(=\text{O})\text{CH}_3$	$-\text{C}(=\text{S})\text{CH}_3$
54	$\text{H}_3\text{CCH}(\text{S})\text{NHCH}_2\text{CH}_2\text{CN}-$	$-\text{CH}_2\text{CF}_3$		$-\text{C}_7\text{H}_{15}$	$-\text{CO}_2\text{COC}(\text{CH}_3)_3$	-H
55	$\text{H}_3\text{C}_6\text{CHN}(\text{H}_3\text{C}_6\text{H}_2\text{C})\text{CH}_2\text{CN}-$		$-\text{C}_2\text{H}_5$	$-\text{C}_6\text{H}_7$	$-\text{CNHC}(=\text{O})\text{CH}_2\text{CO}_2\text{H}$	$-\text{C}_6\text{H}_5$
56		-H	$-\text{CH}_2\text{C}_6\text{H}_5$	$-\text{C}_9\text{H}_{19}$	$\text{CNHC}(=\text{O})\text{CH}(\text{C}_6\text{H}_5)\text{CO}_2\text{CH}_3$	$-\text{C}(=\text{S})\text{CH}_3$
57	$\text{H}_3\text{COOC}(\text{CH}_2)_2\text{N}(\text{HOOCH}_2\text{C})-$	-H	$-(\text{CH}_2)_2\text{C}_6\text{H}_5$	$-(\text{CH}_2)_2-\text{O}-\text{C}_6\text{H}_5$	$-\text{CNHC}(=\text{O})\text{CH}(\text{CH}_3)\text{CO}_2\text{C}_2\text{H}_5$	$-\text{CF}_3$



30	25	20	15	10	5
Example	R ⁷	X	Y	Z	m n p
49	-H	-CH ₂	-CH ₂	-	2 2 2
50	$\begin{array}{c} \text{O} \\ \parallel \\ -\text{CH}_2\text{NHCCH}_3 \end{array}$	-CH ₂ -	$\begin{array}{c} \text{COCH}_3 \\ \\ -\text{N}- \end{array}$	$\begin{array}{c} \text{C}_4\text{H}_9 \\ \\ -\text{CH} \end{array}$	6 0 0
51	-H	-S-	-CH ₂ -	$\begin{array}{c} \text{CH}_3 \\ \\ -\text{CH} \end{array}$	3 1 1
52	-CH ₃	-SO	-CH ₂ -	-	0 0 5
53	-F	-SO ₂	-NH	-	8 1 2
54	$\begin{array}{c} \text{S} \\ \parallel \\ -\text{COC}_2\text{H}_5 \end{array}$	$\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}- \end{array}$	-NH	$\begin{array}{c} \text{C}_3\text{H}_7 \\ \\ -\text{CH} \end{array}$	4 2 2
55	$\begin{array}{c} \text{O} \\ \parallel \\ -\text{CH}_2\text{CCH}_3 \end{array}$	$\begin{array}{c} \text{S} \\ \parallel \\ -\text{C}- \end{array}$	-NH	$\begin{array}{c} -\text{CH} \\ \\ \text{C}_5\text{H}_4\text{N} \\ \\ \text{OH} \end{array}$	6 1 3
56	-F	-CH=CH-	-NCH ₃	$\begin{array}{c} \text{F}_3\text{C} \\ \\ \text{C}_6\text{H}_4 \\ \\ \text{CH}- \end{array}$	2 2 2
57	-H	-C≡C-	-NCH ₃	$\begin{array}{c} \text{C}_5\text{H}_4\text{O} \\ \\ \text{CH}_2\text{CH} \end{array}$	3 4 1

This Sheet Has Been Replaced



EXAMPLE 58

Blood was drawn into 0.1 volumes of acid-citrate-dextrose (85 mM sodium citrate, 64 mM
5 citric acid, 110 mM dextrose) by venipuncture from normal human volunteers. Platelet-rich plasma was prepared by centrifugation at 400 x g for 12 minutes. PGE1 (5 mg/ml) was added and platelets were collected by centrifugation at 800 x g for 12
10 minutes. The platelet pellet was resuspended into human platelet buffer (140 mM NaCl, 7.9 mM KCl, 3.3 mM Na₂HPO₄, 6 mM HEPES, 2% bovine serum albumin, 0.1 % dextrose, pH 7.2) and filtered over Sepharose 2B that was previously equilibrated in human platelet
15 buffer. Platelets were counted and adjusted to 2 x 10⁸/ml with human platelet buffer. Human fibrinogen (10-100 mg/ml and CaCl₂ (1 mM) were added and aggregation was initiated by the addition of 10 mM ADP. Aggregation was monitored by the initial rate
20 of increase of light transmittance.

While the invention has been described and illustrated in reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various changes, modifications and
25 substitutions can be made therein without departing from the spirit and scope of the invention. For example, effective dosages other than the preferred doses as set forth hereinabove may be applicable as a consequence of variations in the responsiveness of
30 the mammal being treated for severity of clotting disorders or emboli, or for other indications for the compounds of the invention indicated above.

This Sheet Has Been Replaced

Likewise, the specific pharmacological responses observed may vary according to and depending upon the particular active compound selected or whether there are present pharmaceutical carriers, as well as the
5 type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be
10 limited only by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.

15

20

25

30

This Sheet Has Been Replaced


58/RSP35

- 103 -

181971A

WHAT IS CLAIMED IS:


1. A compound of the structural formula



and the pharmaceutically acceptable salts thereof,
wherein

15 R^1 is a four to eight member heterocyclic ring
containing 1, 2, 3 or 4 heteroatoms wherein
said heteroatoms are N, O or S and wherein
said heterocyclic ring is optionally
substituted at any atom by H, R^6 or R^7 ; NR^6R^7

20 $R^6R^7N-C(=O)-$; $R^6R^7N-C(=O)-NH-$; $R^6-C(=O)-NR^7-$;



wherein R^6 and R^7 are independently
hydrogen and
unsubstituted or substituted C_{0-10} alkyl and
cycloalkyl wherein said substituents are

30 C_{1-10} alkoxy,
 C_{1-10} alkoxyalkyl,
 C_{1-10} alkoxyalkyloxy,



This Sheet Has Been Replaced



- 5 C₁₋₁₀ alkoxy carbonyl,
C₁₋₁₀ alkyl carbonyl,
C₄₋₁₀ aralkyl carbonyl,
C₁₋₁₀ alkyl thiocarbonyl,
C₁₋₁₀ aralkyl thiocarbonyl,
thiocarbonyl,
C₁₋₁₀ alkoxy thiocarbonyl,
aryl,
- 10 a 5 to 6 membered saturated
heterocyclic ring containing 1, 2, 3 or
4 heteroatoms wherein said heteroatoms
are taken from the group consisting of
N, O and S,
- 15 C₁₋₄ alkanoylamino,
C₁₋₆ alkoxy carbonyl-C₀₋₆ alkylamino,
C₁₋₁₀ alkylsulfonylamino,
C₄₋₁₀ aralkylsulfonylamino,
C₄₋₁₀ aralkyl,
C₁₋₁₀ alkaryl,
- 20 C₁₋₁₀ alkylthio,
C₄₋₁₀ aralkylthio,
C₁₋₁₀ alkylsulfinyl,
C₄₋₁₀ aralkylsulfinyl,
C₁₋₁₀ alkylsulfonyl,
- 25 C₄₋₁₀ aralkylsulfonyl,
aminosulfonyl,
C₁₋₁₀ alkylaminosulfonyl,
C₄₋₁₀ aralkylsulfonylamino,
- 30 oxo,
thio,



* C L M S *



58/RSP35

- 105 -

18197IA

5 unsubstituted and mono- and
di-substituted 1-ethenyl, 2-ethenyl and
3-propenyl wherein said substituents
are selected from the group consisting
of hydrogen, C₁₋₁₀ alkyl and C₄₋₁₀
aralkyl,
carboxy,
hydroxy,
amino,
10 C₁₋₆ alkylamino,
C₁₋₆ dialkylamino,
halogen, where halogen is defined as F,
Cl, Br or I,
nitro, and
15 cyano,
and further wherein said N can additionally
be substituted to form a quaternary ammonium
ion wherein said substituent is as
previously defined for R⁶ and R⁷;
20 R² and R³ are independently
hydrogen,
aryl and
unsubstituted and substituted C₀₋₁₀ alkyl and
25 cycloalkyl wherein said substituent is
C₁₋₁₀ alkoxyalkyl,
aryl,

30



* C L M S *



58/RSP35

- 106 -

18197IA

a 4 to 8 membered saturated
heterocyclic ring system containing 1,
2, 3 or 4 hetero atoms, wherein said
hetero atoms are taken from the group
consisting of N, O and S,

5 C₄₋₁₀ aralkyl,
C₁₋₁₀ alkaryl,
C₁₋₁₀ alkylthio,
C₄₋₁₀ aralkylthio,

10 C₁₋₁₀ alkylsulfinyl,
C₄₋₁₀ aralkylsulfinyl,
C₁₋₁₀ alkylsulfonyl,
C₄₋₁₀ aralkylsulfonyl,
carboxy,

15 C₁₋₁₀ alkylcarbonyl,
C₁₋₁₀ alkylthiocarbonyl,
C₄₋₁₀ aralkylcarbonyl,
C₄₋₁₀ aralkylthiocarbonyl,
C₁₋₆ alkoxy carbonyl,

20 C₄₋₁₀ aralkoxy carbonyl,
C₁₋₆ alkoxy,
C₁₋₆ alkoxy carbonyl-C₁₋₄ alkyl,
C₄₋₁₀ aralkoxy carbonyl-C₁₋₄ alkyl,
C₄₋₁₀ aralkoxy,

25 C₁₋₆ alkylamino,
C₁₋₁₂ dialkylamino,
C₁₋₆ alkanoylamino,
C₄₋₁₀ aralkanoylamino,
C₄₋₁₀ aralkylamino,

30



* C L H S *



58/RSP35

- 107 -

18197IA


R⁴ is

- aryl,
C₁₋₁₀ alkyl or cycloalkyl,
C₄₋₁₀ aralkyl,
5 C₁₋₁₀ alkoxyalkyl,
C₁₋₁₀ alkaryl,
C₁₋₁₀ alkylthioalkyl,
C₁₋₁₀ alkoxythioalkyl,
C₁₋₁₀ alkylamino,
10 C₄₋₁₀ aralkylamino,
C₁₋₁₀ alkanoylamino,
C₄₋₁₀ aralkanoylamino,
C₁₋₁₀ alkanoyl,
C₄₋₁₀ aralkanoyl, and
15 unsubstituted or substituted C₁₋₁₀ carboxyalkyl
wherein said substituent is aryl or C₁₋₁₀ aralkyl;
further wherein any of the substituents for R⁴ may be
substituted by a substituent selected from the group
as defined for R⁶;

20 R⁵ is

a four to eight member saturated or unsaturated
heterocyclic ring containing 1, 2, 3 or 4
heterocyclic atoms wherein said heteroatoms are
N, O and S and

25



30



* C L M S *



58/RSP35

- 108 -

181971A

$$\begin{array}{c} \text{S} \\ \parallel \\ -\text{C}-\text{R}^8 \end{array}$$
, wherein R^8 is
hydroxy,

- C_{1-10} alkyloxy,
 C_{1-10} alkaryloxy,
 C_{4-10} aralkyloxy,
 C_{4-10} aralkylcarbonyloxy,
 C_{1-10} alkoxyalkyloxy,
 C_{1-10} alkoxyalkylcarbonyloxy,
 C_{1-10} alkoxycarbonylalkyl,
 C_{1-10} alkylcarbonyloxyalkyloxy,
 an L- or D-amino acid joined by an amide linkage
 or
 an L- or D-amino acid joined by an amide linkage
 and wherein the carboxylic acid moiety of said
 amino acid is esterified by C_{1-6} alkyl or C_{4-10}
 aralkyl,

$$\begin{array}{c} \text{O} \\ \parallel \\ -\text{P}-\text{OR}^9 \end{array}$$
,

$$\begin{array}{c} \text{O} \\ \parallel \\ -\text{P}-\text{OR}^9 \\ | \\ \text{OR}^{10} \end{array}$$
, wherein R^9 and R^{10} are selected from the
 group consisting of hydrogen, C_{1-10} alkyl and C_{4-10}
 aralkyl;

30



* C L M S *

X and Y are optional substituents that, when present
are independently

NR⁶,

O,
S, SO, $\overset{\text{O}}{\parallel}\text{-C-}$; $\overset{\text{S}}{\parallel}\text{-C-}$; $\overset{\text{OH}}{\mid}\text{-CH-}$

SO₂,


$\overset{\text{R}^6}{\mid}\text{-C}=\overset{\text{R}^7}{\mid}\text{-C-}$,

$\text{-C}\equiv\text{C-}$,


a 4- to 8-membered ring containing 0, 1, 2, 3 or
4 heteroatoms chosen from N, O and S, wherein
said ring is independently substituted at any
atom with R⁶

aryl,

or



NR⁶SO₂-; -SO₂NR⁶-; or



Z is an optional substituent that, when present, is
independently chosen as defined for X and Y;

m is an integer of from zero to ten;

n is an integer of from zero to ten; and

p is an integer of from zero to three.






58/RSP35

- 110 -

18197IA

2. A compound of the structural formula



and the pharmaceutically acceptable salts thereof,
wherein

R^1 is

15 a four to eight member heterocyclic ring wherein
said heteroatoms are N, O or S and wherein said
heterocyclic ring is optionally substituted by

C_{1-10} alkyl; or

NR^6R^7 wherein R^6 and R^7 are independently

20 hydrogen,

unsubstituted or substituted C_{1-10} alkyl
wherein said substituent is

C_{1-10} alkoxy carbonyl,

aryl,

25 C_{0-5} dialkylamino- C_{1-10} alkyl,

C_{4-10} aralkyl,

and further wherein said N can additionally be
substituted to form a quaternary ammonium ion wherein
30 said substituent is as previously defined for R^6 and
 R^7 ;



* C L M S *



58/RSP35

- 111 -

18197IA

R^2 and R^3 are independently
hydrogen,
 C_{1-4} alkyl or C_{4-10} aralkyl;

5 R^4 is
aryl,
 C_{1-10} alkyl or cycloalkyl,
 C_{4-10} aralkyl,
 C_{1-10} alkoxyalkyl or
10 unsubstituted or substituted C_{1-10} carboxyalkyl
wherein said substituent is aryl or C_{1-10} aralkyl;
 R^{11} is
hydrogen or
 C_{1-10} alkyl;

15 X and Y are independently
O,
 SO_2 ,
20 $-CH=CH-$, $-\overset{\overset{O}{\parallel}}{C}NR^6-$, $-NR^6\overset{\overset{O}{\parallel}}{C}-$, SO_2NR^6- , or $-NR^6SO_2-$
aryl,
a 5- or 6-membered ring containing 0, 1 or 2
heteroatoms chosen from N, O and S wherein said
ring is independently substituted at any atom
25 with R^6 ;

Z is an optional substituent that, when present, is

30 O, SO_2 , $-NR^6CO-$, $-CONR^6-$, $-\overset{\overset{O}{\parallel}}{C}-$
 C_{1-10} straight or branched alkyl;



* C L M S *




58/RSP35

- 112 -

181971A

m is an integer of from zero to eight;
 n is an integer of from zero to two; and
 p is an integer of from zero to two structural formula

5 3. A compound of the structural formula



and the pharmaceutically acceptable salts thereof,
 15 wherein

R^1 is

a five to six member heterocyclic ring containing
 one or two heteroatoms wherein said heteroatoms
 20 are N, O or S and wherein said heterocyclic ring
 is optionally substituted by C_{1-5} alkyl; or
 NR^6R^7 wherein R^6 and R^7 are independently

hydrogen,

unsubstituted or substituted C_{1-10} alkyl
 25 wherein said substituent is

C_{4-10} aralkyl,

and further wherein said N can additionally be
 substituted to form a quaternary ammonium ion wherein
 said substituent is as previously defined for R^6 and
 30 R^7 ;



* C L M S *



58/RSP35

- 113 -

18197IA

R^2 and R^3 are hydrogen;

R^4 is

5 aryl,
 C_{1-10} alkyl,
 C_{4-10} aralkyl,

R^{11} is

 hydrogen or
 C_{1-10} alkyl;

10

X and Y are independently

O O
 $\parallel$ $\parallel$
0, -NHC-, -C-NH-,
 -CH=CH-, -CH₂-, or C_{1-10} cycloalkyl;

15

Z is an optional substituent that, when present, is

0, SO₂, -NHCO-,
 C_{1-10} straight or branched alkyl;

20 m is an integer of from zero to six;
n is an integer of from zero to one; and
p is an integer of from zero to one.

25

30



* C L N S *




58/RSP35

- 114 -

18197IA

4. A compound of the structural formula



and the pharmaceutically acceptable salts thereof,
wherein

R^1 is

15 a six member saturated heterocyclic ring
containing one or two heteroatoms
wherein said heteroatoms are N or O and wherein
said heterocyclic ring is optionally substituted
by C_{1-3} alkyl; or

20 NR^6R^7 wherein R^6 and R^7 are independently
hydrogen or
 C_{1-10} alkyl;

R^4 is

aryl,
25 C_{1-10} alkyl or
 C_{4-10} aralkyl;

X and Y are independently

C_{1-10} alkyl or cycloalkyl $-NHC(=O)-$ or $-CNH(=O)-$;

30





58/RSP35

- 115 -


181971A

Z is an optional substituent that, when present, is
 O, -NHCO-, or -CONH-
 C₁₋₅ straight or branched alkyl;

- 5 m is an integer of from zero to six;
 n is one or two; and
 p is zero or one.

5. A compound of the structural formula

10



wherein

- 20 R¹ is
 a six member saturated heterocyclic ring
 containing one or two heteroatoms wherein said
 heteroatoms are N;

NR⁶R⁷ wherein R⁶ and R⁷ are independently

- 25 H or
 C₁₋₁₀ alkyl;

R⁴ is

- 30 aryl
 C₁₋₁₀ alkyl
 C₄₋₁₀ aralkyl;





58/RSP35

- 116 -

18197IA


Z is

0, $-\text{NHC}(=\text{O})-$, $-\text{C}(=\text{O})\text{NH}-$, where m is an integer from two to six.

5


6. A compound as claimed in Claim 5, of the structural formula

10




15

20





25

30



* C L M S *

This Sheet Has Been Replaced



7. A pharmaceutical composition comprising a compound as claimed in Claim 1 or Claim 6 and a pharmaceutically acceptable carrier.

8. The use of a compound as claimed in Claim 1 or Claim 6 for the manufacture of a medicament for blocking fibrinogen from acting as its platelet receptor site in a mammal.

9. The use of a compound as claimed in Claim 1 or Claim 6 for the manufacture of a medicament for the prevention or treatment of thrombus formation.

10. The use of a compound as claimed in Claim 1 or Claim 6 together with an anti-coagulant agent for blocking fibrinogen from acting at its platelet receptor site in a mammal.



* C L M S *



58/RSP35

- 118 -

18197IA

11. The use of a compound as claimed in Claim 1 or Claim 6 together with an anti-coagulant agent for the prevention or treatment of thrombus formation.

5 12. The use of a compound as claimed in Claim 1 or Claim 6 together with a fibrinolytic agent for blocking fibrinogen from acting at its platelet receptor site in a mammal.

10 13. The use of a compound as claimed in Claim 1 or Claim 6 together with a fibrinolytic agent for the prevention or treatment of thrombus formation.

15 14. The use of a compound as claimed in Claim 1 or Claim 6 together with a platelet anti-aggregation agent for blocking fibrinogen from acting at its platelet receptor site in a mammal.

20 15. The use of a compound as claimed in Claim 1 or Claim 6 together with a platelet anti-aggregation agent for the prevention or treatment of thrombus formation.

25 16. The composition as claimed in Claim 7, further comprising at least one compound selected from the group consisting of platelet anti-aggregation agents, thrombolytic agents and anti-coagulation agents.

30



* C L M S *